



## 2012 Fact Book

---

The information set forth in this publication is compiled and amended annually by the budget and finance staff of the National Cancer Institute and is intended primarily for the use by members of the Institute and others involved in the administration and management of the National Cancer Program. It is available online at <http://www.cancer.gov>. Questions regarding any of the information contained herein may be directed to the Office of Budget and Finance, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892

# TABLE OF CONTENTS

---

<b>Executive Summary</b>	Fiscal Year 2012 Annual Report.....	iii
<b>Organization</b>	Director's Biography.....	O-1
	Former Directors of the NCI.....	O-2
	National Cancer Advisory Board.....	O-4
	NCI-Frederick Advisory Committee .....	O-8
	Clinical Trials and Translational Research Advisory Committee .....	O-10
	Boards of Scientific Counselors and Advisors .....	O-14
	President's Cancer Panel .....	O-15
	Scientific Program Leaders.....	O-15
	NCI Director's Consumer Liaison Group.....	O-16
	Operational Organization Charts:	
	National Cancer Institute .....	O-17
	Office of the Director .....	O-18
	OD I: Office of Management .....	O-19
	OD II: Center for Biomedical Informatics and Information Technology .....	O-20
	OD II: Office of Science Planning and Assessment.....	O-20
	OD III: Office of Communications and Education .....	O-21
	OD IV: Center for Cancer Genomics .....	O-22
	OD V: Center to Reduce Cancer Health Disparities .....	O-23
	OD V: Center for Strategic and Scientific Initiatives.....	O-23
	Center for Cancer Research.....	O-24
	Division of Cancer Biology .....	O-26
	Division of Cancer Epidemiology and Genetics .....	O-27
	Division of Cancer Prevention.....	O-28
	Division of Cancer Control and Population Sciences.....	O-29
	Division of Cancer Treatment and Diagnosis.....	O-30
	Division of Extramural Activities.....	O-31
<b>Cancer Statistics</b>	Links to Cancer Statistics.....	C-1
<b>Budget Data</b>	NCI Budget .....	B-1
	Program Structure .....	B-2
	Extramural Funds .....	B-3
	NCI Obligations by Mechanism.....	B-4
	Division Obligations by Mechanism .....	B-5
	NIH Management Fund, Service & Supply Fund and GSA Rent... ..	B-6
	Special Sources of Funds .....	B-7
	Funding for Various Research Areas.....	B-8
<b>Extramural Programs</b>	Research Project Grants:	
	Number of Awards .....	E-1
	Requested, Awarded .....	E-2
	Awards by Activity Code .....	E-3
	Activity Code Descriptions .....	E-4
	Cancer Centers By State .....	E-5
	Specialized Programs of Research Excellence (SPORE) .....	E-6

National Research Service Awards – Pre and Post Doctoral Trainees .....	E-7
Construction/Renovation Funding and Building & Facilities .....	E-8
Grant and Contract Awards by State .....	E-9
Grant and Contract Awards by Country .....	E-10
Institutions Receiving More than \$15,000,000 in NCI Support .....	E-11

**Historical Trends**

Appropriations of the NCI .....	H-1
Bypass Budget Requests .....	H-2
Comparison of Bypass Requests and Appropriations of the NCI .....	H-3
Comparison of Dollars, Positions and Space .....	H-4
Personnel Resources .....	H-5
AIDS Funding History .....	H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Office of Budget and Finance homepage at <http://obf.cancer.gov/> on the National Cancer Institute’s website: [www.nci.nih.gov](http://www.nci.nih.gov) or [www.cancer.gov](http://www.cancer.gov).

## Executive Summary

---

### Fiscal Year 2012 Annual Report

#### BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2012 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.cancer.gov>).

#### Summary

Funds available to the NCI in FY 2012 totaled over \$5.067 billion, reflecting an increase of 0.2% and \$9.2 million from the previous fiscal year.

Fiscal highlights from FY 2012 include:

- Of the total NCI budget, 42.4% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,021 (includes SBIR).
- Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- 1,085 competing RPGs were funded.
- One-third of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 7<sup>th</sup> percentile.
- 190 grants – totaling over \$77 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research comprised about 17% of the total NCI budget in FY 2012. Of this amount, about two thirds were for Labs and Bench Research and the remaining one-third was for infrastructure and support.

**NCI Dollars by Mechanism for FY 2011 and 2012**  
(in thousands)

	2011	2012	Change '11 to '12	
			Am't	%
Research Project Grants:				
Noncompeting	1,631,514	1,639,445	7,931	0.5%
Admin Supplements	23,619	19,819	-3,800	-16.1%
Competing	424,494	414,004	-10,490	-2.5%
Subtotal, RPG	2,079,627	2,073,268	-6,359	-0.3%
SBIR/STTR	84,054	77,355	-6,699	-8.0%
Total, RPG	2,163,681	2,150,624	-13,057	-0.6%
Cancer Centers	278,345	279,877	1,532	0.6%
SPOREs	121,868	113,454	-8,414	-6.9%
Other P50s/P20s	35,172	33,438	-1,734	-4.9%
Other Specialized Centers	162,652	186,020	23,368	14.4%
Total: Centers, Spec Ctrs, & SPOREs	598,037	612,789	14,752	2.5%
Research Career Program	73,615	73,164	-451	-0.6%
Cancer Education	32,590	33,372	782	2.4%
Clinical Cooperative Groups	243,880	229,842	-14,038	-5.8%
Other Grants	75,546	71,164	-4,382	-5.8%
Subtotal, Other	425,631	407,542	-18,089	-4.2%
Total, Research Grants	3,187,349	3,170,954	-16,395	-0.5%
National Research Service Awards	67,654	65,992	-1,662	-2.5%
R&D Contracts	587,035	589,715	2,680	0.5%
Intramural Research	833,670	857,841	24,171	2.9%
Research Management & Support	374,477	374,919	442	0.1%
Construction	-	-	-	0.0%
Buildings and Facilities	7,920	7,920	-	0.0%
Total, NCI	5,058,105 *	5,067,342 **	9,237	0.2%
AIDS research included above	[269,953]	[271,692]	1,739	0.6%

\*Cancer Prevention and Control was eliminated as a Budget Mechanism in FY09.

\*\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.


## Percent Share of Total NCI Dollars

### Summary Points

- The mechanism shares of the total budget have remained relatively stable from FY 2008 to FY 2012, taking into account the elimination of Cancer Prevention and Control as a budget mechanism in FY 2009.

Percent Share of Total NCI Dollars					
	2008	2009	2010	2011	2012
<b>Research Project Grants</b>	43.3%	43.0%	42.5%	42.8%	42.4%
<b>Cancer Centers</b>	5.7%	5.8%	5.8%	5.5%	5.5%
<b>SPOREs</b>	2.6%	2.6%	2.6%	2.4%	2.2%
<b>Specialized Centers</b>	1.6%	2.3%	2.8%	3.2%	3.7%
<b>Other P50s/P20s</b>	-	0.6%	0.8%	0.7%	0.7%
<b>Clinical Cooperative Groups</b>	3.0%	4.7%	5.0%	4.8%	4.5%
<b>R&amp;D Contracts</b>	9.2%	12.3%	12.0%	11.6%	11.6%
<b>Intramural Research</b>	14.9%	15.7%	15.8%	16.5%	16.9%
<b>Cancer Prevention &amp; Control*</b>	9.9%	0.0%	0.0%	0.0%	0.0%
<b>Other Mechanisms</b>	9.9%	13.0%	12.7%	12.5%	12.4%

\*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.



## Funding Trends

### Summary Points

- The NCI budget has increased by \$239.7 million – or 5.0% – since FY 2008.

	<b>Historical Funding Trends</b>				
	(Dollars in Millions)				
	<b>2008</b>	<b>2009</b>	<b>2010</b>	<b>2011</b>	<b>2012</b>
<b>Total NCI</b>	\$4,827.6	\$4,967.0	\$5,098.1	\$5,058.1	\$5,067.3
<b>Research Project Grants</b>	2,089.9	2,134.0	2,168.1	2,163.7	2,150.6
<b>Cancer Centers</b>	274.5	285.6	295.9	278.3	279.9
<b>SPOREs</b>	123.3	131.4	133.8	121.9	113.5
<b>Other P50s/P20s</b>	-	28.1	38.8	35.2	33.4
<b>Other Specialized Centers</b>	79.3	116.4	142.7	162.7	186.0
<b>Clinical Cooperative Groups</b>	144.0	234.5	254.5	243.9	229.8
<b>R&amp;D Contracts</b>	444.2	610.1	613.8	587.0	589.7
<b>Intramural Research</b>	718.4	781.4	805.3	833.7	857.8
<b>*Cancer Prevention &amp; Control</b>	471.5	-	-	-	-
<b>Other Mechanisms</b>	482.5	645.5	645.4	631.8	626.5

	<b>% Growth by Mechanism</b>				
	<b>2008 to 2009</b>	<b>2009 to 2010</b>	<b>2010 to 2011</b>	<b>2011 to 2012</b>	<b>2008 to 2012</b>
<b>Total NCI</b>	2.9%	2.6%	-0.8%	0.2%	5.0%
<b>Research Project Grants</b>	2.1%	1.6%	-0.2%	-0.6%	2.9%
<b>Cancer Centers</b>	4.0%	3.6%	-5.9%	0.6%	2.0%
<b>SPOREs</b>	6.6%	1.8%	-8.9%	-6.9%	-8.0%
<b>Other P50s/P20s</b>	-	-	100.0%	-4.9%	100.0%
<b>Specialized Centers</b>	46.8%	22.6%	14.0%	14.4%	134.6%
<b>Clinical Cooperative Groups</b>	62.8%	8.5%	-4.2%	-5.8%	59.6%
<b>R&amp;D Contracts</b>	37.3%	0.6%	-4.4%	0.5%	32.8%
<b>Intramural Research</b>	8.8%	3.1%	3.5%	2.9%	19.4%
<b>*Cancer Prevention &amp; Control</b>	-100.0%	-	-	-	-100.0%
<b>Other Mechanisms</b>	33.8%	0.0%	-2.1%	-0.8%	29.9%

\*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.

## Research Project Grants

### Summary Points

- About half of competing dollars supported grants awarded within the established payline and RFAs and half supported grants as an exception to the payline.
- RFA funds accounted for 10.1% of FY 2012 competing dollars.
- Research Project Grant applications submitted to NCI decreased slightly.
- A total of 1,085 competing RPG's were funded.

<b>Research Project Grants*</b>				
(Dollars in Thousands)				
	<b>2011</b>		<b>2012</b>	
	<b>No.</b>	<b>Amount</b>	<b>No.</b>	<b>Amount</b>
Total funding for RPGs	5,019	\$2,163,681	5,021	\$2,150,624
SBIR/STTR	144	\$84,054	190	\$77,355
Funding for RPGs without SBIR/STTR Program	4,875	\$2,079,627	4,831	\$2,073,268
Continuation or noncompeting grants funded	3,769	\$1,655,132	3,746	\$1,659,264
Competing grants funded	1,106	\$424,494	1,085	\$414,004
Administrative Supplements	206	\$23,619	184	\$19,819
Partial assessment for DHHS Program Evaluation		\$75,329		\$75,329
Funds set aside within competing dollars for:				
Grants within Paylines:	588	\$188,865	574	\$174,255
Traditional R01	338	\$138,517	352	\$136,052
Program Projects (P01)	-	-	-	-
RFA Grants	68	\$32,131	88	\$41,677
Share of competing grant funds		7.6%		10.1%
Exception Grants	474	\$217,335	482	\$228,534
Share of competing grant funds		51.2%		55.2%
Competing Application Requests	8,037	\$3,336,074	8,014	\$3,069,520
Funding Success Rate		13.8%		13.5%
Percentile funding for R01 grants		7th		7th
Average Cost-Competing		\$384		\$382
Average Reduction from recommended/requested levels		-17%		-17%


\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

### Grant Funding Paylines

RPG Mechanisms:	2011	2012	
R01 Traditional Grants	7th	7th	percentile
P01 Program Projects*	N/A	N/A	priority score
R03 Small Grants	25	25	priority score
R21 Exploratory Phase I	7th	7th	percentile
R33 Exploratory Phase II	Case by Case	Case by Case	priority score
R41/R42 STTR	20	23	priority score
R43/R44 SBIR	24	24	priority score

\* Formal paylines for P01 grants are determined by the Scientific Program Leadership (SPL) Committee.

### National Cancer Institute FY 2012 % Share of Total RPG Funds




**National Cancer Institute  
Extramural vs. Inhouse Funding**  
(dollars in millions)

Mechanism	Extramural					08 - 12% chg.
	2008	2009	2010	2011	2012	
Research Project Grants	\$2,089.9	\$2,137.0	\$2,168.1	\$2,163.7	\$2,150.6	2.9%
Cancer Centers	274.5	285.6	295.9	278.3	279.9	2.0%
SPOREs	123.3	131.4	133.8	121.9	113.5	-8.0%
Other P50s/P20s	-	28.1	38.8	35.2	33.4	100.0%
Other Specialized Centers	79.3	116.4	142.7	162.7	186.0	134.6%
Other Research Grants	317.8	417.3	442.5	425.5	407.5	28.2%
NRSA	69.9	70.1	67.6	67.7	66.0	-5.6%
R&D Contracts	444.2	610.1	613.8	587.0	589.7	32.8%
Cancer Control Grants*	190.4	-	-	-	-	-100.0%
Cancer Control Contracts*	134.8	-	-	-	-	-100.0%
Construction	-	-	-	-	-	0.0%
Buildings & Facilities	7.9	7.9	7.9	7.9	7.9	0.0%
<b>Total Extramural Funds</b>	<b>3,732.0</b>	<b>3,803.9</b>	<b>3,911.0</b>	<b>3,849.9</b>	<b>3,834.5</b>	<b>2.7%</b>

Mechanism	Inhouse					08 - 12% chg.
	2008	2009	2010	2011	2012	
Intramural Research	\$718.4	\$781.4	\$805.3	\$833.7	\$857.8	19.4%
RMS	231.0	384.6	381.8	374.5	374.9	62.3%
Control Inhouse*	146.3	-	-	-	-	-100.0%
<b>Total Inhouse Funds</b>	<b>1,095.7</b>	<b>1,166.0</b>	<b>1,187.1</b>	<b>1,208.2</b>	<b>1,232.8</b>	<b>12.5%</b>
<b>Total NCI</b>	<b>4,827.7</b>	<b>4,969.9</b>	<b>5,098.1</b>	<b>5,058.1</b>	<b>5,067.3</b>	<b>5.0%</b>

\*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.




## Research Career Awards – “K” Program

### *Summary Points*

- The Research Career Award mechanism decreased by 0.6% in FY 2012.
- The number of Research Career Awards decreased by 16 between FY 2011 and FY 2012.
- NCI funded 53 awards for the NIH Pathway to Independence program.

		(Dollars in Thousands)			
		2011		2012	
		No.	Amount	No.	Amount
K01	Temin Awards	8	\$1,110	51	\$6,487
K01	Minority Mentored Career Development Award	48	6,265		0
	Subtotal, K01s	56	7,375	51	6,487
K05	Research Scientist Award	25	3,741	23	3,453
K07	Preventive Oncology	88	12,257	76	10,941
K08	Clinical Investigator	91	14,129	105	16,479
K12	Institutional Clinical Oncology Research	18	12,424	18	13,398
K18	Career Enhancement Award for Stem Cell Research	1	117	1	117
K22	Transition Career Development	28	4,827	25	4,452
K23	Patient-Oriented Career	38	5,937	36	3,676
K24	Patient-Oriented Career -- Mid Career	16	2,860	17	5,143
K25	Mentored Quantitative Research Career Development Award	21	2,868	17	2,274
K30	Institutional Curriculum Awards -- Administered by NCRR	0	0	0	0
K99	NIH Pathway to Independence Awards	56	7,080	53	6,744
	Total Research Career Program	438	73,615	422	73,164

**National Cancer Institute**  
**FY 2012**  
**% of Total Research Award Funds**



## Research Dollars by Various Cancers

### *Summary Points*

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget
- Based on NCI Coding Methodology.

Research Dollars by Various Cancers (Dollars in Millions)					
	2008	2009	2010	2011	2012
Total NCI	\$4,827.6	\$4,966.9	\$5,098.1	\$5,058.1	\$5,067.3
AIDS	258.5	265.9	272.1	270.0	271.7
Brain & Central Nervous System	153.7	151.5	156.8	172.6	177.5
Breast Cancer	586.8	599.4	631.2	625.1	602.7
Cervical Cancer	76.8	70.8	77.0	81.4	72.6
Clinical Trials	853.2	882.8	852.3	877.8	753.7
Colorectal Cancer	273.7	264.1	270.4	265.1	256.3
Head and Neck	76.1	77.1	62.7	61.8	65.0
Hodgkin's Disease	17.5	18.2	14.6	13.4	15.6
Leukemia	216.4	220.5	239.7	227.0	234.7
Liver Cancer	74.2	69.0	72.6	66.2	64.6
Lung Cancer	247.6	246.7	281.9	296.8	315.1
Melanoma	110.8	103.7	102.3	115.6	121.2
Multiple Myeloma	41.5	45.2	48.5	54.9	61.3
Non Hodgkin's Lymphoma	122.6	131.3	122.4	126.4	119.5
Ovarian Cancer	100.0	110.1	112.3	110.8	111.7
Pancreatic Cancer	87.3	89.6	97.1	99.5	105.4
Prostate Cancer	285.4	285.1	300.5	288.3	265.1
Stomach Cancer	12.4	15.4	14.5	13.4	12.1
Uterine Cancer	17.1	18.0	14.2	15.9	19.1

# National Cancer Institute

---

## Director's Biography Harold Varmus, M.D.

Harold Varmus became Director of the National Cancer Institute on July 12, 2010.

Harold Varmus, co-recipient of the Nobel Prize for studies of the genetic basis of cancer, served 10 years as President of Memorial Sloan-Kettering Cancer Center and six years as Director of the National Institutes of Health. He is a member of the U.S. National Academy of Sciences and the Institute of Medicine and is involved in several initiatives to promote science and health in developing countries. The author of over 350 scientific papers and five books, including a recent memoir titled The Art and Politics of Science, he was a co-chair of President Obama's Council of Advisors on Science and Technology, was a co-founder and Chairman of the Board of the Public Library of Science, and chaired the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

## Former Directors of the National Cancer Institute

---

**John E. Niederhuber, M.D.**  
June 2006 – September 2006 (Acting)  
September 2006 – July 2010

John E. Niederhuber, M.D., became Director of the National Cancer Institute (NCI), one of the National Institutes of Health, in September 2006. He joined NCI in a full-time capacity in September 2005 as Deputy Director for Translational and Clinical Sciences and within a few weeks was asked to serve as Chief Operating Officer. He officially became NCI's Acting Director in June 2006. Dr. Niederhuber has also served as the Chair of the National Cancer Advisory Board, as an external NCI advisor and grant reviewer, and as a laboratory investigator supported by NCI and the NIH.

**Andrew C. von Eschenbach, M.D.**  
January 2002 – September 2005

Andrew C. von Eschenbach, M.D., became the 12<sup>th</sup> NCI Director in January 2002. He previously directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.

**Richard D. Klausner, M.D.**  
August 1995 – September 2001

Dr. Klausner was appointed as the Director of the NCI on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development.

**Samuel Broder, M.D.**  
December 1988 – March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program.

**Vincent T. DeVita, Jr., M.D.**  
January 1980 – June 1980 (Acting)  
July 1980 – August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

**Arthur Canfield Upton, M.D.**  
July 1977 – December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

**Frank Joseph Rauscher, Jr., Ph.D.**  
May 1972 – October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

**Carl Gwin Baker, M.D.**  
November 1969 – July 1970 (Acting)  
July 1970 – April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

**Kenneth Milo Endicott, M.D.**  
July 1960 – November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.

**John Roderick Heller, M.D.**  
May 1948 – June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

## Former Directors of the National Cancer Institute (continued)

---

**Leonard Andrew Scheele, M.D.**  
July 1947 – April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

**Roscoe Roy Spencer, M.D.**  
August 1943 – July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

**Carl Voegtlin, Ph.D.**  
January 1938 – July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

# National Cancer Advisory Board (NCAB)

---

## Membership and Term

### Chairperson

- 2016 Tyler E. Jacks, Ph.D.  
Koch Institute for Integrative Cancer Research  
Massachusetts Institute of Technology  
Cambridge, MA 02157
- 2012 Anthony Atala, M.D.  
Wake Forest Institute for Regenerative Medicine  
Department of Urology  
Wake Forest University School of Medicine  
Winston-Salem, NC 27157
- 2012 Bruce A. Chabner, M.D.  
Massachusetts General Hospital Cancer Center  
Massachusetts General Hospital  
Boston, MA 02114
- 2014 Victoria L. Champion, D.N.S.  
Center for Research & Scholarship  
Indiana University School of Nursing  
Indianapolis, IN 46202
- 2018 David C. Christiani, M.D., M.P.H.\*  
Elkan Blout Professor of Environmental Genetics  
Departments of Environmental Health and  
Environmental and Occupational Medicine and  
Epidemiology  
Harvard School of Public Health  
Professor of Medicine  
Harvard Medical School  
Boston, MA 02115
- 2012 Donald S. Coffey, Ph.D.  
Departments of Urology/Oncology/Pathology  
Pharmacology and Molecular Science  
Johns Hopkins University School of Medicine  
Baltimore, MD 21287
- 2016 Marcia R. Cruz-Correa, M.D., Ph.D.  
University of Puerto Rico  
Basic and Translational Science Director  
University of Puerto Rico  
Comprehensive Cancer Center  
San Juan, Puerto Rico
- 2016 Kevin J. Cullen, M.D.  
Marlene and Stewart Greenebaum Cancer Center  
University of Maryland  
Professor of Medicine  
University of Maryland  
Baltimore, MD 21201
- 2018 Judy E. Garber, M.D., M.P.H.\*  
Director  
Center for Cancer Genetics and Prevention  
Dana Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School  
Boston, MA 02215
- 2014 William H. Goodwin, Jr.  
CCA Industries, Inc.  
Richmond, VA 23219
- 2014 Waun Ki Hong, M.D.  
Department of Thoracic/Head & Neck  
Medical Oncology  
The University of Texas M.D. Anderson  
Cancer Center  
Houston, TX 77030
- 2018 Elizabeth M. Jaffee, M.D.\*  
The Dana and Albert "Cubby" Broccoli  
Professor of Oncology  
Co-Director of the Gastrointestinal Cancers  
Program  
Associate Director for Translational Research  
The Sidney Kimmel Comprehensive Cancer  
Center at Johns Hopkins University  
Baltimore, MD 21231
- 2018 Beth Y. Karlan, M.D.\*  
Director, Women's Cancer Program  
Samuel Oschin Comprehensive Cancer Institute  
Director of Gynecologic Oncology  
Department of Obstetrics & Gynecology  
Cedar-Sinai Medical Center  
Professor, Obstetrics and Gynecology  
David Geffen School of Medicine, UCLA  
Los Angeles, CA 90048
- 2012 Mr. Robert A. Ingram  
Hatteras Venture Partners  
Durham, NC 27701
- 2012 Judith S. Kaur, M.D.  
Native American Programs  
Mayo Comprehensive Cancer Center  
Department of Medical Oncology  
Mayo Clinic  
Rochester, MN 55905

## National Cancer Advisory Board (NCAB)

---

### Membership and Term

2014 Mary Vaughan Lester  
University of California  
San Francisco Foundation  
Los Angeles, CA 99024

2014 H. Kim Lyerly, M.D.  
Duke University School of Medicine  
Durham, NC 27705

2012 Karen M. Meneses, Ph.D.  
School of Nursing  
University of Alabama at Birmingham  
Birmingham, AL 35294

2016 Olufunmilayo I. Olopade, M.B.B.S., F.A.C.P.  
Center for Clinical Cancer Genetics  
University of Chicago  
Pritzker School of Medicine  
Chicago, IL 60637

2014 Jennifer A. Pietenpol, Ph.D.  
Vanderbilt-Ingram Cancer Center  
Vanderbilt University Medical Center  
Nashville, TN 37232

2018 Mack Roach III, M.D., F.A.C.R.\*  
Professor of Radiation Oncology and Urology  
Chair, Department of Radiation Oncology  
University of California, San Francisco  
Helen Diller Family Comprehensive Cancer Center  
San Francisco, CA 94143

2016 Johnathan M. Samet, M.D., M.S.  
Professor and Flora L. Thornton Chair  
Department of Preventative Medicine  
Keck School of Medicine  
Director, Institute for Global Health  
University of Southern California  
Los Angeles, CA

2018 Charles L. Sawyer, M.D.\*  
Chairman  
Human Oncology and Pathogenesis Program  
Memorial Sloan-Kettering Cancer Center  
Investigator  
Howard Hughes Medical Institute  
Professor of Medicine  
Weill-Cornell Medical College  
New York, NY 10065

2016 William R. Sellers, M.D.  
Vice President/Global Head of Oncology  
Novartis Institutes for BioMedical Research, Inc.  
Cambridge, MA

#### Executive Secretary

Paulette S. Gray, Ph.D.

#### Committee Management Officer

Ms. Claire L. Harris

\* Newly appointed member pending personnel paperwork

## National Cancer Advisory Board (Continued)

---

### Ex Officio Members

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.  
Director  
National Institute of Environmental Health  
Sciences and The National Technology Program  
National Institutes of Health  
Research Triangle Park, NC

Francis S. Collins, M.D., Ph.D.  
Director  
National Institutes of Health  
Bethesda, MD

Margaret A. Hamburg, M.D.  
Commissioner  
Food and Drug Administration  
Silver Spring, MD

John P. Holdren, Ph.D.  
Science Advisor to the President  
Director  
Office of Science and Technology Policy  
Executive Office of the President  
Washington, DC

John Howard, M.D., M.P.H., J.D., LL.M.  
Director  
National Institute for Occupational Safety and Health  
Washington, DC

Lisa Jackson, M.S.  
Administrator  
Environmental Protection Agency  
Washington, DC

The Honorable Dr. Michael J. Kussman  
Under Secretary for Health  
Veterans Health Administration  
Department of Veterans Affairs  
Washington, DC

Anna Palmisano, Ph.D.  
Associate Director, Office of Biological and  
Environmental Research  
Department of Energy  
Washington, DC

The Honorable Kathleen Sebelius, M.P.A.  
Secretary  
Department of Health and Human Services  
Washington, DC

The Honorable Hilda L. Solis  
Secretary  
Department of Labor  
Washington, DC

Inez Tenenbaum, M.Ed.  
Chairman  
Consumer Product Safety Commission  
Bethesda, MD

Jonathan Woodson, M.D.  
Assistant Secretary of Defense for Health Affairs  
The Pentagon  
Washington, DC

## National Cancer Advisory Board (Continued)

---

### Alternates to Ex Officio Members

Michael A. Babich, Ph.D.  
Directorate for Epidemiology and Health Sciences  
Consumer Product Safety Commission  
Bethesda, MD  
**(Ms. Inez Tenenbaum- CPSC)**

Patricia Bray, M.D., M.P.H.  
Acting Director, Office of Occupational Medicine  
OSHA / Department of Labor  
Washington, DC  
**(The Honorable Hilda L. Solis- DOL)**

Michael Kelley, M.D., F.A.C.P.  
National Program Director for Oncology  
Veterans Health Administration  
Department of Veterans Affairs  
Durham, NC  
**(The Honorable Dr. Michael J. Kussman)**

Aubrey Miller, M.D.  
Senior Medical Officer  
National Institute of Environmental Health  
Sciences  
National Institutes of Health  
Bethesda, MD  
**(Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.- NIEHS)**

Richard Pazdur, M.D.  
Division Director  
Division of Oncology Drugs  
Food and Drug Administration  
Rockville, MD  
**(Margaret A. Hamburg, M.D. - FDA)**

John F. Potter, M.D.  
Director  
United States Military Cancer Institute  
Walter Reed National Military Medical Institute  
Bethesda, MD  
**(Jonathan Woodson, M.D. - DHA)**

R. Julian Preston, Ph.D.  
Associate Director for Health  
Environmental Protection Agency  
Research Triangle Park, NC  
**(Lisa Jackson, M.S. - EPA)**

Michael Stebbins, Ph.D.  
Assistant Director, Biotechnology  
Office of Science and Technology Policy  
Executive Office of the President  
Washington, DC  
**(John P. Holdren, Ph.D. -OSTP)**

Marie H. Sweeney, Ph.D., M.P.H.  
Chief  
Surveillance Branch  
Division of Surveillance  
Hazard Evaluations & Field Studies,  
National Institute for Occupational Safety  
and Health  
Cincinnati, Ohio  
**(John Howard, M.D., M.P.H., J.D., LL.M.- NIOSH)**

Lawrence A. Tabak, D.D.S., Ph.D.  
Principal Deputy Director  
National Institutes of Health  
Bethesda, MD  
**(Francis S. Collins, M.D., Ph.D.)**

Sharlene Weatherwax, Ph.D.  
Director  
Biological Systems Sciences Division  
Office of Biological and Environmental Research  
Office of Science  
U.S. Department of Energy  
Washington, DC  
**(Anna Palmisano, Ph.D. - DOE)**

**Note: Bold print represents Ex Officio Members**

## NCI-Frederick Advisory Committee (NFAC)

---

### Membership and Term

#### Chairperson

- 2013 Zach W. Hall, Ph.D.  
President Emeritus  
Institute for Regenerative Medicine  
University of California, San Francisco  
Wilson, WY 83014
- 2014 J. Carl Barrett, Ph.D.  
Vice-President  
Translational Sciences Onc iMed  
AstraZeneca  
Waltham, MA 02451
- 2013 David Botstein, Ph.D.  
Anthony B. Evnin Professor of Genomics  
Department of Molecular Biology  
Director  
Lewis-Sigler Institute  
Princeton University  
Princeton, NJ 08544
- 2016 Vicki L. Colvin, Ph.D.\*  
Vice-Provost  
Kenneth S. Pitzer-Schlimberger  
Professor of Chemistry  
Rice University  
Houston, TX 77005
- 2015 Levi A. Garraway, M.D., Ph.D.  
Assistant Professor of Medicine  
Department of Medical Oncology  
Dana-Farber Cancer Institute  
Harvard Medical School  
Boston, MA 02115
- 2013 Joe W. Gray, Ph.D.  
Gordon Moore Endowed Chair  
Chair, Department of Biomedical Engineering  
Director, OHSU Center for Spatial Systems  
Biomedicine  
Oregon Health and Science University  
Portland, OR
- 2015 Beatrice H. Hahn, M.D.  
Professor of Medicine  
Division of Hematology/Oncology  
University of Pennsylvania  
Philadelphia, PA 19104
- 2014 Jennifer A. Pietenpol, Ph.D.  
Director  
Vanderbilt-Ingram Cancer Center  
B.F. Byrd, Jr. Professor of Oncology  
Professor of Biochemistry  
Vanderbilt University Medical Center  
Nashville, TN 37232
- 2014 Steven T. Rosen, M.D., F.A.C.P.  
Genevieve Teuton Professor of Medicine  
Department of Medicine  
Feinberg School of Medicine  
Director, Robert H. Lurie Comprehensive  
Cancer Center  
Northwestern University  
Robert H. Lurie Medical Research Center  
Chicago, IL 60611
- 2015 Cheryl L. Willman, M.D.  
Maurice and Marguerite Liberman  
Distinguished Chair in Cancer Research  
Director and CEO  
Cancer Research and Treatment Center  
University of New Mexico  
Albuquerque, NM 87131
- 2014 Monica J. Justice, Ph.D.  
Professor  
Department of Molecular and Human Genetics  
Baylor College of Medicine  
Houston, TX 77030
- 2013 Thomas A. Look, M.D.  
Vice Chair for Research  
Department of Pediatric Oncology  
Dana-Farber Cancer Institute  
Boston, MA 02115
- 2015 Lawrence J. Marnett, Ph.D.  
Director  
Vanderbilt Institute of Chemical Biology  
Mary Geddes Stahlman Professor of Biochemistry  
Chemistry, and Pharmacology  
Director, A.B. Hancock Jr. Memorial Laboratory  
Director, Vanderbilt Institute of Chemical Biology  
Vanderbilt University Medical Center  
Nashville, TN 37232

## NCI-Frederick Advisory Committee (NFAC) (Continued)

---

### Membership and Term

2013 Jill P. Mesirov, Ph.D.  
Chief Informatics Officer  
Broad Institute of MIT and Harvard  
Director  
Computational Biology and Bioinformatics  
Cambridge, MA 02142

2015 Kenneth Olden, Ph.D., Sc.D., L.H.D.  
Director  
National Center for Environmental Assessment  
Office of Research and Development  
Environmental Protection Agency  
Washington, DC 20460

2015 Garry P. Nolan, Ph.D.  
Rachford and Carlota A. Harris Professor  
Baxter Laboratory in Genetic Pharmacology  
Department of Microbiology & Immunology  
Director, Stanford University Proteomics Center  
Stanford University  
Stanford, CA 94305

2016 Kenneth J. Pienta, M.D.  
Associate Vice President for Research,  
Health Sciences  
Professor of Internal Medicine and Urology  
The University of Michigan  
Ann Arbor, MI 48109

#### Executive Secretary

Thomas M. Vollberg, Sr., Ph.D.

\* Newly appointed member pending personnel paperwork

### Ex Officio Members

John Czajkowski, M.P.A.  
Deputy Director for Management  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

James H. Doroshov, M.D.  
Deputy Director  
Clinical and Translational Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

Paulette S. Gray, Ph.D.  
Director  
Division of Extramural Activities  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

Douglas R. Lowy, M.D.  
Deputy Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

Alan S. Rabson, M.D.  
Deputy Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

Craig W. Reynolds, Ph.D.  
Associate Director  
National Cancer Institute  
Frederick National Laboratory for  
Cancer Research  
National Institutes of Health  
Frederick, MD

Margaret A. Tucker, M.D.  
Acting Director  
Division of Cancer Epidemiology  
and Genetics  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

Robert H. Wiltout, Ph.D.  
Director  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

# Clinical Trials and Translational Research Advisory Committee (CTAC)

---

## Membership and Term

- Chair**
- 2012 **James L. Abbruzzese, M.D., F.A.C.P.**  
Chairman  
Department of Gastrointestinal Medical Oncology  
The University of Texas M.D. Anderson Cancer Center  
Houston, TX
- 2013 **Peter C. Adamson, M.D.**  
Chair, Children's Oncology Group  
Chief, Division of Clinical Pharmacology & Therapeutics  
The Children's Hospital of Philadelphia  
University of Pennsylvania  
Philadelphia, PA
- 2014 **Susan G. Arbuck, M.D., M.Sc., F.A.C.P.**  
President  
Susan G. Arbuck, M.D., LLC  
Potomac, MD
- 2014 **Monica M. Bertagnolli, M.D.**  
Professor of Surgery Harvard Medical School  
Brigham & Women's Hospital  
Dana-Farber Cancer Institute  
Boston, MA
- 2013 **Susan G. Braun (DCLG)**  
Executive Director  
Commonwealth  
Bolinas, CA
- 2012 **Curt Civin, M.D. (BSA)**  
Associate Dean of Research  
Professor of Pediatrics  
Director  
Center for Stem Cell Biology and Regenerative Medicine  
University of Maryland School of Medicine  
Baltimore, MD
- 2012 **Kenneth H. Cowan, M.D., Ph.D.**  
Director  
Eppley Institute for Cancer Research  
University of Nebraska Medical Center  
Omaha, NE
- 2015 **Kevin J. Cullen, M.D. (NCAB)**  
Director  
University of Maryland Greenebaum Cancer Center  
Baltimore, MD
- 2015 **Nancy E. Davidson, M.D.**  
Director  
University of Pittsburgh Cancer Institute  
University of Pittsburgh  
Pittsburgh, PA
- 2013 **Olivera J. Finn, Ph.D.**  
Distinguished Professor and Chair  
University of Pittsburgh School of Medicine  
Pittsburgh, PA
- 2015 **J. Phillip Kuebler, M.D., Ph.D.**  
Principal Investigator  
Columbus Oncology Associates, Inc.  
Columbus, OH
- 2013 **Scott M. Lippman, M.D.**  
Professor and Chair  
Department of Thoracic/Head and Neck Medical Oncology  
The U. of Texas M.D. Anderson Cancer Center  
Houston, TX
- 2014 **Mary S. McCabe, R.N.**  
Director  
Cancer Survivorship Program  
Memorial Sloan Kettering Cancer Center  
New York, NY
- 2016 **Edith P. Mitchell, M.D., FACP\***  
Director, Center for Elimination of Cancer Disparities  
Kimmel Cancer Center at Jefferson  
Thomas Jefferson University  
Philadelphia, PA
- 2016 **Nikhil C. Munshi, M.D.\***  
Associate Professor of Medicine  
Hematologic Oncology Treatment Center  
Dana Farber Cancer Institute  
Boston, MA
- 2014 **Lisa A. Newman, M.D., M.P.H., F.A.C.S.**  
Professor of Surgery and Director, Breast Cancer Center and Multidisciplinary Breast Fellowship Program  
U. of Michigan Comprehensive Cancer Center  
Ann Arbor, MI
- 2013 **Nancy Roach (BSC)**  
Consumer Advocate  
C3: Colorectal Cancer Coalition  
Hood River, OR
- 2013 **Daniel J. Sargent, Ph.D.**  
Director  
Cancer Center Statistics  
Professor  
Mayo Clinic College of Medicine  
Mayo Clinic Foundation  
Rochester, MN

## Clinical Trials and Translational Research Advisory Committee (Continued)

---

### Membership and Term

2013 **Mitchell D. Schnall, M.D., Ph.D.**

Matthew J. Wilson Professor  
University of Pennsylvania Medical Center  
Philadelphia, PA

2014 **Peter G. Shields, M.D.**

Deputy Director  
Comprehensive Cancer Center  
Professor  
College of Medicine  
The Ohio State University Medical Center  
Columbus, OH

2015 **George W. Sledge, Jr., M.D.**

Professor  
Departments of Medicine and Pathology  
Co-leader  
Breast Cancer Program  
Indiana University Cancer Center  
Indianapolis, IN

2016 **Chris H.M. Takimoto, M.D., Ph.D., FACP\***

Vice President  
Translational Medicine Early Development  
Oncology Therapeutics Area  
Janessen Research and Development  
Pharmaceutical Companies of Johnson and Johnson  
Radnor, PA

2012 **Joel E. Tepper, M.D.**

Hector MacLean Distinguished Professor of Cancer  
Research  
Department of Radiation Oncology  
University of North Carolina  
Lineberger Comprehensive Cancer Center  
Chapel Hill, NC

2014 **Gillian M. Thomas, M.D., FRCPC, FRCR**

Professor  
Department of Radiation Oncology  
Department of Obstetrics and Gynecology  
University of Toronto  
Odette Cancer Centre  
Sunnybrook Health Sciences Centre  
Toronto, Ontario  
Canada

2014 **Frank M. Torti, M.D., M.P.H. (BSA)**

Vice President for Strategic Programs  
Wake Forest Baptist Medical Center  
Chair  
Cancer Biology  
Charles L. Spurr Professor of Medicine  
Director

2014 **Miguel A. Villalona-Calero, M.D.**

Professor of Medical Oncology  
Division of Hematology and Oncology  
The Ohio State University  
Columbus, OH

2015 **George J. Weiner, M.D.**

C.E. Block Chair of Cancer Research  
Professor  
Department of Internal Medicine  
Director  
Holden Comprehensive Cancer Center  
Iowa City, Iowa

### Executive Secretary

Sheila A. Prindiville, M.D., MPH

\*Ad hoc Members

## **Clinical Trials and Translational Research Advisory Committee (Continued)**

---

### **Ex Officio Members**

**James H. Doroshow, M.D.**

Deputy Director  
Clinical and Translational Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Paulette Gray, Ph.D.**

Director  
Division of Extramural Activities  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Rosemarie Hakim, Ph.D., M.S.**

Epidemiologist  
Centers for Medicare and Medicaid Services  
Baltimore, MD

**Lee Helman, M.D.**

Chief  
Pediatric Oncology Branch  
Scientific Director for Clinical Research  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Michael J. Kelley, M.D., F.A.C.P.**

National Program Director for Oncology  
Veterans Health Administration  
Department of Veterans Affairs  
Washington, DC

**Richard Pazdur, M.D., F.A.C.P.**

Director  
Division of Oncology Drug Products  
U.S. Food and Drug Administration  
Rockville, MD

**TBD**

United States Military Cancer Institute  
Walter Reed National Military Medical Institute  
Bethesda, MD

**Alan Rabson, M.D.**

Deputy Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

## **Clinical Trials and Translational Research Advisory Committee (Continued)**

---

### **Ad Hoc Subcommittee**

#### **NCI Clinical Trials Strategic Planning Ad Hoc Subcommittee**

**James L. Abbruzzese, M.D. (Chair)**

Chairman  
Department of Gastrointestinal Medical Oncology  
The University of Texas M.D. Anderson Cancer Center  
Houston, TX

**Nancy E. Davidson, M.D.**

Director  
University of Pittsburgh Cancer Institute  
University of Pittsburgh  
Pittsburgh, PA

**Scott M. Lippman, M.D.**

Director  
UC San Diego Moores Cancer Center  
La Jolla, CA

**Nancy A. Roach (BSC)**

Consumer Advocate  
C3: Colorectal Cancer Coalition  
Hood River, OR

**Joel E. Tepper, M.D.**

Hector MacLean Distinguished Professor of  
Cancer Research  
Department of Radiation Oncology  
University of North Carolina  
Lineberger Comprehensive Cancer Center  
Chapel Hill, NC

**George J. Weiner, M.D.**

C.E. Block Chair of Cancer Research  
Professor  
Department of Internal Medicine  
Director  
Holden Comprehensive Cancer Center  
Iowa City, Iowa

#### **NCI Liaisons**

**Jeffrey S. Abrams, M.D.**

Acting Director  
Division of Cancer Treatment and Diagnosis  
National Cancer Institute

**James H. Doroshow, M.D.**

Deputy Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Leslie G. Ford, M.D.**

Associate Director for Clinical Research  
Office of the Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Lori Minasian, M.D., F.A.C.P.**

Acting Director  
Division of Cancer Prevention  
National Cancer Institute

#### **Executive Secretary**

**Sheila A. Prindiville, M.D., M.P.H.**

Director  
Coordinating Center for Clinical Trials  
Office of the Director  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

#### **CTAC Working Groups**

**Pancreatic Cancer Working Group**

**NCI National Clinical Trials Network (NCTN) Working Group**

## Board of Scientific Counselors Intramural Programs

### Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
<b>Chair - Ethan Dmitrovsky, M.D.</b>	<b>2013</b>	Raphael E. Pollock, M.D., Ph.D.	2016
Edgar Ben-Josef, M.D.	2014	David Poplack, M.D.	2014
Jonine L. Bernstein, Ph.D. *	2017	Jeremy Rich, M.D.*	2017
Arthur W. Blackstock, Jr., M.D.	2016	Nancy Roach	2013
Tim Byers, M.D.	2015	Thomas Rohan, M.D., Ph.D.	2014
Susan Chang, M.D.	2013	Thomas A. Sellers, Ph.D.	2013
Susan Cohn, M.D.*	2017	Darryl K. Shibata, M.D.	2015
Marc T. Goodman, Ph.D.	2015	Walter Stadler, M.D.*	2017
Bernard Harlow, Ph.D.	2014	Robert E. Tigelaar, M.D.	2013
Carl June, M.D.	2014	Walter J. Urba, M.D., Ph.D.	2013
Karen L. Kelly, M.D.	2015	Elizabeth Ward, Ph.D.	2014
Hongzhe Lee, Ph.D.	2016	Louis Weiner, M.D.*	2017
Alexandra M. Levine, M.D.	2015	George Wilding, M.D.	2016
Sanford Markowitz, M.D., Ph.D.	2016	Cheryl L. Willman, M.D.	2015
Augusto Ochoa, M.D.	2014		
Kenneth Offit, M.D.	2016	Executive Secretary - Brian Wojcik, Ph.D.	

### Basic Sciences

<b>Chair - Joan W. Conaway, Ph.D.</b>	<b>2015</b>	Jonathan D. Licht, M.D.	2014
Paul D. Bieniasz, Ph.D.	2014	A. Thomas Look, M.D.	2013
John C. Cambier, Ph.D.	2015	Ian G. Macara, Ph.D.	2014
Lawrence Corey, M.D.	2014	Roeland Nusse, Ph.D.	2017
Sara A. Courtneidge, Ph.D.	2016	Suzanne Ostrand-Rosenberg, Ph.D.	2014
Norman Drinkwater, Ph.D.	2014	Thomas L. Poulos, Ph.D.	2015
Errol Friedberg, M.D.	2014	James H. Prestegard, Ph.D.	2013
Joanna Groden, Ph.D.	2016	Kenneth L. Rock, M.D.	2015
Daria J. Hazuda, Ph.D.	2015	James A. Wells, Ph.D.	2016
Eric Hunter, Ph.D.	2015	Tzzy-Choou Wu, M.D., Ph.D.	2017
Stephen D. Hursting, Ph.D.	2017	Wayne M. Yokoyama, M.D.	2016
Chris M. Ireland, Ph.D.	2013	Virginia A. Zakian, Ph.D.	2015
Alexandra L. Joyner, Ph.D.	2016	Dong-Er Zhang, Ph.D.	2017
Marcelo G. Kazanietz, Ph.D.	2015		
Robert E. Lewis, Ph.D.	2016	Executive Secretary - Florence E. Farber, Ph.D.	

## Board of Scientific Advisors Extramural Programs

<b>Chair - Todd R. Golub, M.D.</b>	<b>2015</b>	Chanita Hughes-Halbert, Ph.D.	2017
Francis Ali-Osman, D.Sc.	2016	Joshua LaBaer, M.D., Ph.D.	2014
Ethan M. Basch, M.D., M.Sc.*	2017	Theodore S. Lawrence, M.D., Ph.D.	2016
Sangeeta N. Bhatia, M.D., Ph.D.	2016	Mr. Donald Listwin	2014
Andrea Califano, Ph.D.	2013	Maria E. Martinez, Ph.D., M.P.H.	2015
Arul M. Chinnaiyan, M.D., Ph.D.	2015	Luis F. Parada, Ph.D.	2016
Curt I. Civin, M.D.	2015	Martine F. Roussel (Sherr), Ph.D.*	2017
Graham A. Colditz, M.D., Dr.Ph.*	2017	Kevin M. Shannon, M.D.*	2017
Chi V. Dang, M.D., Ph.D.	2014	Mary L. Smith, J.D., M.B.A.*	2017
Robert B. Diasio, M.D.	2013	Lincoln Stein, M.D., Ph.D.	2016
Daniel A. DiMaio, M.D., Ph.D.*	2017	Bruce W. Stillman, Ph.D.	2015
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.	2014	Louise C. Strong, M.D.	2013
Brian J. Druker, M.D.	2016	Frank M. Torti, M.D., M.P.H.	2014
Karen M. Emmons, Ph.D.	2016	Gregory L. Verdine, Ph.D.	2016
Betty Ferrell, Ph.D., RN, F.A.A.N.	2015	Cheryl L. Walker, Ph.D., A.T.S., F.A.A.N.*	2017
Kathleen M. Foley, M.D.	2013	Irving L. Weissman, M.D.	2015
Stanton L. Gerson, M.D.	2016		
Joe W. Gray, Ph.D.	2013	Executive Secretary - Paulette S. Gray, Ph.D.	

\* Newly appointed member pending personnel

## President's Cancer Panel

---

**Barbara K. Rimer, DrPH, MPH 2012**  
Dean and Alumni Distinguished Professor  
Gillings School of Global Public Health  
The University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599

**Owen N. Witte, M.D. 2014**  
Director  
Eli and Edythe Broad Center of Regenerative Medicine  
and Stem Cell Research  
Investigator, Howard Hughes Medical Institute  
University of California, Los Angeles  
Los Angeles, CA 90095

**Hill Harper, J.D. 2013**  
Cancer Survivor  
4 Time New York Times Best-Selling Author, Actor,  
and Philanthropist  
Hollywood, CA

**Abby B. Sandler, Ph.D.**  
Executive Secretary  
NCI Office of the Director  
9000 Rockville Pike  
Bldg. 31, Room B2B37  
Bethesda, MD 20892-2590

---

## Scientific Program Leaders (SPL) Members

---

**Harold Varmus, M.D.**  
Director

**Douglas Lowy, M.D.**  
Deputy Director

**Jeff Abrams, M.D.**  
Acting Director for Clinical Research, Division of  
Cancer Treatment and Diagnosis

**Alan S. Rabson, M.D.**  
Deputy Director

**Robert T. Croyle, Ph.D.**  
Director, Division of Cancer Control and Population  
Sciences

**Dinah S. Singer, Ph.D.**  
Director, Division of Cancer Biology

**John Czajkowski**  
Deputy Director for Management

**Sanya A. Springfield, Ph.D.**  
Director, Center to Reduce Cancer Health Disparities

**James H. Doroshow, M.D.**  
Deputy Director for Clinical and Translational Research

**Joseph Tomaszewski, Ph.D.**  
Acting Director for Preclinical Research, Division of  
Cancer Treatment and Diagnosis

**Joseph F. Fraumeni, Jr., M.D.**  
Director, Division of Cancer Epidemiology and Genetics

**Ted Trimble, M.D., MPH**  
Director, Center for Global Health

**Paulette S. Gray, Ph.D.**  
Director, Division of Extramural Activities

**Michael Weingarten**  
Director, SBIR Development Center

**Peter Greenwald, M.D., Dr.Ph**  
Associate Director for Prevention

**Linda Weiss, Ph.D.**  
Director, Cancer Centers

**Lee Helman, M.D.**  
Scientific Director for Clinical Research, CCR

**Jonathan Wiest, Ph.D.**  
Director, Center for Cancer Training

**George Komatsoulis**  
Acting Director, Center for Biomedical Informatics  
and Information Technology

**Robert H. Wiltout, Ph.D.**  
Director, Center for Cancer Research

**Barnett S. Kramer, M.D., MPH**  
Director, Division of Cancer Prevention

**Robert Yarchoan, M.D.**  
Director, Office of HIV & AIDS Malignancy


**Joy Wiszneauckas**  
Executive Secretary

## NCI Director's Consumer Liaison Group


---

<b>Ms. Gwen Darien, Chair</b> Chari, DCLG	<b>2013</b>	<b>Mr. Jeff Kaufman</b> Adenoid Cystic Carcinoma Research Foundation	<b>2015</b>
<b>Dr. Jeff Allen</b> Friends of Cancer Research	<b>2013</b>	<b>Mr. Jon Retzlaff</b> American Association for Cancer Research	<b>2014</b>
<b>Mr. David Arons</b> National Brain Tumor Society	<b>2016</b>	<b>Mr. Josh Sommer</b> Chordoma Foundation	<b>2014</b>
<b>Ms. Susan Braun</b> The V Foundation for Cancer Research	<b>2013</b>	<b>Mr. Max Wallace</b> Accelerate Brain Cancer Cure	<b>2013</b>
<b>Dr. Adam Clark</b> U.S. Department of Health and Human Services	<b>2015</b>		
<b>Ms. Andrea Ferris</b> LUNGeivity	<b>2015</b>	<b>Ms. Kelli Marciel</b> Executive Secretary Director, Office of Advocacy Relations National Cancer Institute 31 Center Drive, Room 10A28 Bethesda, MD 20892-2580	
<b>Ms. Joya Delgado Harris</b> American Cancer Society	<b>2015</b>		
<b>Dr. Michelle McMurry-Heath</b> U.S. Food and Drug Administration	<b>2014</b>		
<b>Ms. Linda House</b> Cancer Support Community	<b>2015</b>		

# National Cancer Institute



These organizational charts reflect the operational structure of NCI. Official organizational chart can be found at <http://oma.od.nih.gov/manualchapters/management/1123/nci.pdf>



**Deputy Directors**

Deputy Director  
Dr. Alan Rabson  
301-496-1927

Deputy Director  
Dr. Doug Lowy  
301-827-5699

Deputy Director  
Clinical and Translational Research  
Dr. Jim Doroshow  
301-496-5615

Deputy Director for Management  
Mr. John Czajkowski  
301-435-2455

**Office of Public Affairs and Research Communications**  
Director  
Mr. Rick Borchelt  
301-435-5709

**Associate Director for Prevention**  
Dr. Peter Greenwald  
301-451-2474

**Special Assistant to the Director**  
Ms. Amy Bulman  
301-496-9723

**Institute Review Office**  
Chief  
Dr. Mehrdad Tondravi  
301-496-7628

**Office of Advocacy Relations**  
Director  
Ms. Amy Bulman  
301-496-9723

**Office of Management**  
Deputy Director for Management (Executive Officer)  
Mr. John Czajkowski  
301-435-2455

**Center for Biomedical Informatics and Information Technology**  
Acting Director  
Dr. George Komatsoulis  
301-451-2881

**Office of Science Planning and Assessment**  
Acting Director  
Dr. Margaret Ames  
301-402-7519

**Office of Communications and Education**  
Director  
Dr. Lenora Johnson  
301-451-4056

**Center for Cancer Genomics**  
Acting Directors  
Dr. Stephen J. Chanock  
Dr. Louis Staudt  
301-435-7559

**Office of Cancer Centers**  
Director  
Dr. Linda Weiss  
301-496-8531

**Center for Strategic Scientific Initiatives**  
Acting Director  
Dr. Doug Lowy  
301-827-5699

**Center to Reduce Cancer Health Disparities**  
Director  
Dr. Sanya A. Springfield  
301-496-8589

**Center for Cancer Training**  
Director  
Dr. Jonathan Wiest  
301-435-9030

**Coordinating Center for Clinical Trials**  
Director  
Dr. Sheila Prindiville  
301-451-5041

**Office of HIV and AIDS Malignancy**  
Director  
Dr. Robert Yarchoan  
301-496-0328

**SBIR Development Center**  
Director  
Mr. Michael S. Weingarten  
301-496-4413

**NCI-Frederick Office of Scientific Operations**  
Associate Director  
Dr. Craig Reynolds  
301-846-5693

**Center for Global Health**  
Director  
Dr. Ted Trimble  
301-496-1045

**Office of Management**  
 Deputy Director for Management  
 (Executive Officer)  
 Mr. John Czajkowski  
 301-435-2455

**Employee Relations Group**  
 Gwyn Collins  
 301-435-3620

**Deputy Executive Officer**  
 Ms. Anne Lubenow  
 301-435-7780

**Administrative Resource Center - OD**  
 Director  
 Ms. Cathy Ng  
 301-435-2961

**Administrative Resource Center - DCTD**  
 Director  
 Mr. Joe Jenkins  
 301-594-5965

**Administrative Resource Center - DCCPS/DCP**  
 Director  
 Ms. Joy Osborne  
 301-496-0010

**Administrative Resource Center - DCB/DEA**  
 Director  
 Ms. Bridgette Tobiassen  
 301-496-2871

**Technology Transfer Center**  
 Director  
 Ms. Karen Maurey  
 301-496-0477

**Office of Budget and Finance**  
 Acting Director  
 Ms. Karen Colbert  
 301-496-5803

**Office of Government and Congressional Relations**  
 Director  
 Ms. Susan Erickson  
 301-496-5217

**Office of Ethics**  
 Director/DEC  
 Ms. Nancy O'Hanlon  
 301-496-1148

**Deputy Executive Officer**  
 Ms. Donna Siegle  
 301-594-7507

**Administrative Resource Center - DCEG**  
 Director  
 Mr. Roberto Minutillo  
 301-594-7510

**IT Resource Center**  
 Director  
 Mr. Bob Barber  
 301-496-1962

**Administrative Resource Center - OM**  
 Director  
 Ms. Sue Kiser  
 301-435-2065

**Administrative Resource Center - CCR**  
 Director  
 Ms. Lori Holliday  
 301-496-6174

**Support Services Branch**  
 Chief  
 Mr. Michael Tucker  
 301-496-4010

**Clinical ARC**  
 ARC Manager  
 Mr. Patrick Miller  
 301-435-2509

**Frederick ARC**  
 ARC Manager  
 Ms. Tanya Sappington  
 301-846-1072

**Basic ARC**  
 ARC Manager  
 Ms. Lisa Kelly  
 301-496-1841

**Office of Workforce Management and Development**  
 Director  
 Ms. Christina Bruce  
 301-435-8524

**Office of Grants Administration**  
 Director  
 Ms. Crystal Wolfrey  
 301-496-8634

**Office of Acquisitions**  
 Director  
 Ms. Kristen Mistichelli  
 301-435-3810

**Office of Extramural Finance and Information Analysis**  
 Director  
 Mr. Nelson Garcia  
 301-435-5205

**Office of Management Policy and Compliance**  
 Director  
 Ms. Roxane Kerr  
 301-435-5786

**Office of Space and Facilities Management**  
 Director  
 Mr. Daryl Paunil  
 301-496-1858

**Workforce Management Branch**  
 Branch Lead  
 Ms. Susan Ettehadih  
 301-435-7978

**Office of Grants Administration**  
 Deputy Director  
 Ms. Crystal Wolfrey  
 301-496-8634

**Epidemiology, Therapeutics and Sciences Branch**  
 Chief  
 Ms. Jackie Holden  
 301-435-3820

**Financial Analysis Branch**  
 Chief  
 Ms. Tenille McCatty  
 301-435-5217

**Management Support Branch**  
 Chief  
 Ms. Alesha Holliday  
 301-594-6008

**Project Management Branch**  
 Chief  
 Mr. Jeffrey Greenblatt  
 301-496-0136

**Training and Organizational Development Branch**  
 Branch Lead  
 Ms. Yasmin Nasser  
 301-435-8524

**Grants Operations Branch**  
 Chief  
 Mr. Jason Ford  
 301-594-2497

**Prevention, Control and Population Sciences Branch**  
 Chief  
 Ms. Teresa Baughman  
 301-435-3800

**Information Analysis and Applications Branch**  
 Chief  
 Ms. Carol L. Smith  
 301-435-5215

**Quality Management/Program Integrity Branch**  
 Chief  
 Ms. Laura Larson  
 301-402-7520

**Business Operations Branch**  
 Chief  
 Mr. Steve Kelley  
 301-451-4066

**Programs and Services Branch**  
 Branch Lead  
 Mr. Leon Espinoza  
 301-435-8524

**Grants Portfolio Management Branch A**  
 Chief  
 Mr. Sean Hine  
 301-846-1005

**Strategic Acquisition Branch**  
 Acting Chief  
 Ms. Anita Hughes  
 301-402-4511

**Branch D**  
 Vacant

**Grants Portfolio Management Branch B**  
 Chief  
 Mr. Shane Woodward  
 301-846-1017

**Treatment and Support Branch**  
 Chief  
 Mr. Matthew Packard  
 301-624-8742

**Grants Portfolio Management Branch C**  
 Chief  
 Ms. Carol Perry  
 301-496-7205

**Management Operations and Support Branch**  
 Acting Chief  
 Mr. Steven Davis  
 301-846-1112

### Center for Biomedical Informatics and Information Technology

Acting Director  
Dr. George Komatsoulis  
301-451-2881

#### Technical Operations

Director  
Mr. Eric Williams  
301-594-0764

#### Scientific Programs

Director  
Vacant

#### Information Management

Director  
Mr. Christo Andonyadis  
301-480-6187

#### Research and Development

Director  
Mr. Daoud Meerzaman  
301-495-0180

### Office of Science Planning and Assessment

Acting Director  
Dr. Margaret Ames  
301-402-7519

Deputy Director  
Vacant

#### Women's Health

Officer  
Dr. Karen Parker  
301-451-9462

#### Science Planning Branch


Chief  
Ms. Karen Parker  
301-451-9462

#### Program Assessment Branch

Chief  
Dr. James Corrigan  
301-435-3856

#### Program Implementation Branch

Chief  
Vacant



## **Center for Cancer Genomics**

Acting Director  
Dr. Stephen J. Chanock  
301-435-7559

Acting Director  
Dr. Louis Staudt  
301-402-1892

Acting Deputy Director  
Dr. Jerry Lee  
301-496-1045

**Office of Cancer Genomics**  
Director  
Dr. Daniela S. Gerhard  
301-451-8027

**The Cancer Genome Atlas  
Program Office**  
Director  
Dr. Kenna Shaw  
301-435-3864

## Center for Strategic Scientific Initiatives

Acting Director  
Dr. Doug Lowy  
301-827-5699

Deputy Director  
Dr. Jerry Lee  
301-496-1045

**Office of Cancer  
Nanotechnology Research**  
Director  
Dr. Piotr Grodzinski  
301-451-8983

**Office of Cancer Clinical  
Proteomics Research**  
Director  
Dr. Henry Rodriguez  
301-451-8883

**Knowledge Management and  
Special Projects Branch**  
Chief  
Ms. Lisa Krueger  
301-451-5115

**Office of Physical  
Sciences-Oncology**  
Director  
Dr. Larry Nagahara  
301-451-3388

## Center to Reduce Cancer Health Disparities


Director  
Dr. Sanya Springfield  
301-496-8589

Deputy Director  
Vacant

**Disparities  
Research Branch**  
Chief  
Dr. Avraham Rasooly  
301-435-9213

**Diversity Training Branch**  
Chief  
H. Nelson Aguila  
301-496-8589

**Center for Cancer Research  
Office of the Director**  
Director  
Dr. Robert Wiltrout  
301-496-4345  
  
Dr. Lee Helman  
Scientific Director for Clinical Research  
301-496-4346



# Center for Cancer Research

## Office of the Director

Director

Dr. Robert Wiltrout

301-496-4345

Dr. Lee Helman

Scientific Director for Clinical Research

301-496-4346

Dr. Jeffrey Strathern  
Deputy Director  
301-846-1274

Dr. Lawrence Samelson  
Deputy Director  
301-496-4346

**Cancer and Developmental  
Biology Laboratory**  
Chief  
Dr. Alan Perantoni  
301-846-6529

**Laboratory of Cancer  
Prevention**  
Chief  
Dr. Nancy Colburn  
301-846-1342

**CCR Nanobiology Program**  
Chief  
Dr. Robert Blumenthal  
301-846-5532

**Experimental Immunology  
Branch**  
Chief  
Dr. Alfred Singer  
301-496-5461

**Laboratory of Metabolism**  
Chief  
Dr. Frank Gonzalez  
301-435-5587

**HIV Drug Resistance Program**  
Director  
Dr. Stephen Hughes

**Laboratory of Cell and  
Developmental Signaling**  
Chief  
Dr. Debbie Morrison  
301-846-1733

**Laboratory of Protein  
Dynamics and Signaling**  
Chief  
Dr. Allan Weissman  
301-846-1222

**Laboratory of Cancer Biology  
and Genetics**  
Co-Chiefs  
Dr. Stuart Yuspa  
301-496-2162  
Dr. Glenn Merlino  
301-496-4270

**Vaccine Branch**  
Chief  
Dr. Jay Berzofsky  
301-496-6874  
Clinical Component Deputy  
Dr. Ron Gress  
301-496-1791

**HIV DRP Retroviral  
Replication Laboratory**  
Chief  
Dr. Stephen Hughes

**Molecular Discovery Program**  
Acting Director  
Dr. Jeffrey Strathern  
301-846-1274

**Macromolecular  
Crystallography Laboratory**  
Chief  
Dr. Alexander Wlodawer  
301-846-5036

**Laboratory of Biochemistry  
and Molecular Biology**  
Chief  
Dr. Shiv Grewal  
301-594-6389

**Host Virus Interaction Branch**  
Acting Chief  
Dr. Stephen Hughes  
301-846-1619

**Chemical Biology Laboratory**  
Chief  
Dr. Joel Schneider  
301-846-5954

**Mouse Cancer Genetics  
Program**  
Co - Directors  
Dr. Lino Tessarollo  
301-846-1202  
Dr. Shyam Sharan  
301-846-5140

**Laboratory of Immune Cell  
Biology**  
Chief  
Dr. Jonathan Ashwell  
301-496-4931

**Laboratory of Genome  
Integrity**  
Chief  
Dr. Andre Nussenzweig  
301-435-6425

**Cancer and Inflammation  
Program**  
Director  
Dr. Giorgio Trinchieri

**Molecular Targets Laboratory**  
Chief  
Dr. James McMahon  
301-846-5391

**Laboratory of Genomic  
Diversity**  
Acting Chief  
Dr. Jeffrey Strathern  
301-846-1274

**Laboratory of Molecular  
Biology**  
Co - Chiefs  
Dr. Ira Pastan  
301-496-4797  
Dr. Susan Gottesman  
301-496-3524

**Basic Research Laboratory**  
Co-Chiefs  
Dr. Lawrence Samelson  
301-496-4346  
Dr. Jeffrey Strathern  
301-846-1274

**Laboratory of Experimental  
Immunology**  
Chief  
Dr. Giorgio Trinchieri  
301-846-1323

**Structural Biophysics  
Laboratory**  
Chief  
Dr. R. Andrew Byrd  
301-846-1407

Krietman Clinical  
Component Deputy  
Dr. Ron Gress  
301-496-1791

**Laboratory of Receptor  
Biology and Gene Expression**  
Chief  
Dr. Gordon Hager  
301-496-9867

**Laboratory of Molecular  
Immunoregulation**  
Chief  
Dr. Joost Oppenheim  
301-846-1551

## **Division of Cancer Biology**

### **Office of the Director**

Director

Dr. Dinah S. Singer  
301-496-8636

Deputy Director  
Dr. Dan Gallahan  
301-496-8636

Associate Director  
Dr. Cheryl Marks  
301-594-8778

Associate Director  
Dr. Suresh Mohla  
301-435-1878

#### **Cancer Etiology Branch**

Chief  
Dr. Don Blair  
301-496-9740

#### **Tumor Biology and Metastasis Branch**

Chief  
Dr. Suresh Mohla  
301-435-1878

#### **Cancer Immunology and Hematology Branch**

Chief  
Dr. R. Allan Mufson  
301-496-7815

#### **DNA and Chromosome Aberrations Branch**

Chief  
Dr. Judith Mietz  
301-496-9326

#### **Cancer Cell Biology Branch**

Chief  
Dr. Barbara Spalholz  
301-496-7028

#### **Structural Biology and Molecular Applications Branch**

Chief  
Dr. Jennifer Couch  
301-435-5226

# Division of Cancer Epidemiology and Genetics

## Office of the Director


Acting Director

Dr. Margaret A. Tucker

301-496-1611

Deputy Director

Vacant



# Division of Cancer Prevention


## Office of the Director

Director

Dr. Barnett Kramer  
301-496-6616

Deputy Director  
Dr. Lori Minasian  
301-496-8541

Associate Director for Clinical Research  
Dr. Leslie G. Ford  
301-496-0265



# Division of Cancer Control and Population Sciences

## Office of the Director


Director  
Dr. Robert Croyle  
301-594-6776

Deputy Director  
Dr. Deborah Winn  
301-594-9499

Senior Advisor for Cancer Surveillance  
Dr. Brenda Edwards  
301-496-8506

**Deputy Director for  
Implementation Science**  
Dr. Russell Glasgow  
301-435-4912

**Office of Cancer  
Survivorship**  
Director  
Dr. Julia H. Rowland  
301-402-2746



# Division of Cancer Treatment and Diagnosis


## Office of the Director

Acting Director  
Dr. Jeff Abrams  
301-496-6138

Acting Director  
Dr. Joseph Tomaszewski  
301-496-6711

**Biometrics Research Branch**  
Chief  
Dr. Richard Simon  
301-496-0975

**Office of Cancer  
Complementary and  
Alternative Medicine**  
Associate Director  
Dr. Jeffrey White  
301-435-7980



# Division of Extramural Activities

## Office of the Director

Director  
Dr. Paulette S. Gray  
301-496-5147

Deputy Director  
Vacant  
301-496-5147

Assistant Director  
Dr. Peter Wirth  
301-496-7565

### Office of Extramural Applications

Associate Director  
Dr. Amir Sahar-Khiz  
301-594-1331

### Program and Review Extramural Staff Training Office

Chief  
Dr. Michael Small  
301-402-0996

### Office of Referral, Review and Program Coordination

Associate Director  
Dr. Shamala Srinivas  
301-594-1224

#### Applied Information Systems Branch

Chief  
Mr. Greg Fischetti  
301-594-1067

#### Research Analysis and Evaluation Branch

Chief  
Ms. Marilyn R. Gaston  
301-594-1111

#### Research Programs Review Branch

Chief  
Dr. Olivia T. Bartlett  
301-594-2501

#### Resources and Training Review Branch

Chief  
Dr. Robert E. Bird  
301-496-7978

#### Program Coordination and Referral Branch

Chief  
Dr. Christopher L. Hatch  
301-594-1403

#### Special Review and Logistics Branch

Chief  
Dr. Kirt J. Vener  
301-496-7174

## Links to Cancer Statistics

---

### SOURCES:

#### **Annual Report to the Nation on the Status of Cancer, 1975-2009**

*Annual Report to the Nation on the Status of Cancer, 1975-2009 provides information related to incidence, death rates, and trends in the United States. The report published January 2013 contains a special feature on the burden and trends in HPV-associated cancers and HPV vaccination coverage levels.*

[http://seer.cancer.gov/report\\_to\\_nation/](http://seer.cancer.gov/report_to_nation/)

#### **Fast Stats**

*Interactive tool providing tables, charts, and graphs with information related to incidence, mortality, survival and stage, prevalence, and lifetime risk (probability of developing or dying from cancer).*

<http://seer.cancer.gov/faststats/>

#### **SEER Cancer Statistics Review, 1975-2009**

*Annually updated tables and graphs displaying cancer statistics by cancer site, year of diagnosis, age, race, sex, and geography, diagnosed between 1975 and 2009. Searchable cancer statistics related to incidence, mortality, survival, prevalence, and lifetime risk.*

[http://seer.cancer.gov/csr/1975\\_2009\\_pops09/](http://seer.cancer.gov/csr/1975_2009_pops09/)

#### **Cancer Stat Fact Sheets**

*Collection of statistical summaries for a number of common cancer types, with information related to incidence, mortality, survival, stage, prevalence, and lifetime risk.*

<http://seer.cancer.gov/statfacts/>

#### **Cancer Prevalence and Cost of Care Projections**

*This site is based on a study that estimates and projects the national cost of cancer care through the year 2020 separately for multiple cancer sites using the most recent available U.S. population projections, cancer incidence, survival, and cost of care data.*

<http://costprojections.cancer.gov/index.html>

### REPORTS:

#### **Costs of Cancer Care, 2010**

[http://progressreport.cancer.gov/doc\\_detail.asp?pid=1&did=2011&chid=105&coid=1026&mid=](http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2011&chid=105&coid=1026&mid=)

#### **Leading Causes of Death in the United States, 1975 and 2008**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_lead\\_cod.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_lead_cod.pdf)

#### **Estimated New Cancer Cases and Deaths for 2011**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_single/sect\\_01\\_table.01.pdf](http://seer.cancer.gov/csr/1975_2008/results_single/sect_01_table.01.pdf)

#### **Person-Years of Life Lost Due to Cancer and Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2008**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_year\\_lost.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_year_lost.pdf)

#### **Incidence, Mortality, and Five-Year Relative Survival Rates by Cancer Site**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_single/sect\\_01\\_table.04\\_2pgs.pdf](http://seer.cancer.gov/csr/1975_2008/results_single/sect_01_table.04_2pgs.pdf)

#### **Annual Percent Change in Incidence and Mortality Rates, 1997-2008**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_graph\\_trends.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_graph_trends.pdf)

#### **Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_inc\\_trends.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_inc_trends.pdf)

#### **Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_mor\\_trends.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_mor_trends.pdf)

#### **Prevalence of Cancer: Estimated Number of Persons Diagnosed with Cancer, 5- and 32-Year Limited Duration**

[http://seer.cancer.gov/csr/1975\\_2008/results\\_merged/topic\\_prevcounts.pdf](http://seer.cancer.gov/csr/1975_2008/results_merged/topic_prevcounts.pdf)

# Fiscal Year 2012 Budget

(Dollars in Thousands)

---

**A. Actual Obligations Resulting From Appropriated Funds:**

FY 2012 Appropriation	\$5,072,183
Transfer under the HHS Secretary's transfer authority	-1,445
Transfer for HHS Alzheimer's research initiative	-3,342
Lapse	-54
<b>Actual Obligations Subtotal</b>	<b>5,067,342</b>

**B. Reimbursable Obligations:**


<b>Reimbursements</b>	<b>52,880</b>
-----------------------	---------------

**C. Total NCI Obligations: \$5,120,222 \***

\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

# Program Structure Fiscal Year 2012

(Dollars in Thousands)




Budget Activity	Amount	Percent
<b>Research:</b>		
Cancer Causation	\$1,232,813	24.3%
Detection and Diagnosis Research	451,716	8.9%
Treatment Research	1,125,431	22.2%
Cancer Biology	739,474	14.6%
<b>Subtotal Research</b>	<b>3,549,434</b>	<b>70.0%</b>
<b>Resource Development:</b>		
Cancer Centers Support	575,068	11.4%
Research Manpower Development	173,777	3.4%
Buildings and Facilities	7,920	0.2%
<b>Subtotal Resource Development</b>	<b>756,765</b>	<b>15.0%</b>
<b>Cancer Prevention and Control</b>	<b>311,412</b>	<b>6.1%</b>
<b>Program Management and Support</b>	<b>449,731</b>	<b>8.9%</b>
<b>*Total NCI</b>	<b>5,067,342</b>	<b>100.0%</b>

\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

# Extramural Funds Fiscal Year 2012

(Dollars in Thousands)



Mechanism	Amount	Percent
<b>Contracts:</b>		
R&D Contracts	589,715	15.4%
Buildings and Facilities	7,920	0.2%
Construction Contracts	0	0.0%
<b>Subtotal Contracts</b>	<b>597,635</b>	<b>15.6%</b>
<b>Grants:</b>		
Research Project Grants	2,075,295	54.1%
Cancer Centers/Specialized Centers/SPORES	612,789	16.0%
NRSA	65,992	1.7%
Other Research Grants	482,871	12.6%
Construction Grants	0	0.0%
<b>Subtotal Grants</b>	<b>3,236,947</b>	<b>84.4%</b>
Total Extramural Funds	3,834,582	100.0%
Total Intramural/RMS	1,232,760	
<b>*Total NCI</b>	<b>\$5,067,342</b>	

\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

## NCI Obligations by Mechanism, Fiscal Year 2012

(Dollars in Thousands)

		Number	Amount	% of Total
<b>Research Project Grants</b>	Non-Competing	3,746	1,639,445	32.4%
	Administrative Supplements	(184)	19,819	0.4%
	Competing	1,085	414,004	8.2%
	Subtotal, without SBIR/STTR Grants	4,831	2,073,268	40.9%
	SBIR/STTR Grants	190	77,355	1.5%
	<b>Subtotal, Research Project Grants</b>	<b>5,021</b>	<b>2,150,624</b>	<b>42.4%</b>
<b>Centers &amp; SPOREs</b>	Cancer Centers Grants-P20/P30	67	279,877	5.5%
	SPOREs-P50	53	113,454	2.2%
	Other P50s/P20s	20	33,438	0.7%
	Other Specialized Centers	113	186,020	3.7%
	<b>Subtotal, Centers</b>	<b>253</b>	<b>612,789</b>	<b>12.1%</b>
<b>Other Research</b>	Career Program			
	Temin & Minority Mentored Awards-K01	51	6,487	0.1%
	Estab. Inv. Award-K05	23	3,453	0.1%
	Preventive Oncology-K07	76	10,941	0.2%
	Clinical Investigator-K08	105	16,479	0.3%
	Clinical Oncology-K12	18	13,398	0.3%
	Stem Cell Research-K18	1	117	0.0%
	Transitional Career Development-K22	25	4,452	0.1%
	Mentored Patient Oriented RCDA-K23	36	3,676	0.1%
	Mid-Career Invest. & Patient Orient. Res-K24	17	5,143	0.1%
	Mentored Quant. Res Career-K25	17	2,274	0.0%
	Inst. Curr. Award-K30	0	0	0.0%
	Pathway to Independence Awards-K99	53	6,744	0.1%
	<b>Subtotal, Career Program</b>	<b>422</b>	<b>73,164</b>	<b>1.4%</b>
	Cancer Education Program-R25	93	33,372	0.7%
	Clinical Cooperative Groups-U10	128	229,842	4.5%
	Minority Biomedical Support-S06	3	355	0.0%
	Rsch Enhance-SC1 & Pilot Research - SC2	1	340	0.0%
	Continuing Education	1	100	0.0%
	Resource Grants-R24/U24	34	64,693	1.3%
	Explor Coop Agreement-U56	0	0	0.0%
	Global Infect. Disease Rsrch Training Prog - D43	9	5,676	0.1%
	Conference Grants-R13	55	0	0.0%
<b>Subtotal, Other Research Grants</b>	<b>746</b>	<b>407,542</b>	<b>8.0%</b>	
<b>Subtotal, Research Grants</b>		<b>6,020</b>	<b>3,170,954</b>	<b>62.6%</b>
<b>NRSA Fellowships</b>	<i>Trainees:</i>	<b>1,342</b>	<b>65,992</b>	<b>1.3%</b>
<b>R&amp;D Contracts</b>	R&D Contracts	497	552,065	10.9%
	SBIR Contracts	67	37,650	0.7%
	<b>Subtotal, Contracts</b>	<b>564</b>	<b>589,715</b>	<b>11.6%</b>
<b>Intramural Research</b>	Program		713,179	14.1%
	NIH Management Fund/SSF Assessment		144,663	2.9%
	<b>Subtotal, Intramural Research</b>	<i>FTEs:</i>	<b>1,916</b>	<b>857,841</b>
<b>RMS</b>	Research Mgmt and Support		333,221	6.6%
	NIH Management Fund/SSF Assessment		41,698	0.8%
	<b>Subtotal, RMS</b>	<i>FTEs:</i>	<b>1,220</b>	<b>374,919</b>
<b>Buildings and Facilities</b>			<b>7,920</b>	<b>0.2%</b>
<b>Construction</b>			<b>0</b>	<b>0.0%</b>
<b>*Total NCI</b>	<i>FTEs:</i>	<b>3,136</b>	<b>5,067,342</b>	<b>100.0%</b>

\*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)


## Division Obligations by Mechanism, Fiscal Year 2012

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								1,564,116	75,329
								19,819	
								414,004	
								1,997,939	75,329
								77,355	
								<b>2,075,295</b>	<b>75,329</b>
							279,877		
		112,810					644		
		13,084		19,785	400		168		
		6,493	32,694	13,689	2,490		130,653		
		<b>132,387</b>	<b>32,694</b>	<b>33,475</b>	<b>2,890</b>		<b>411,343</b>		
							6,487		
							3,453		
							10,941		
							16,479		
							13,398		
							117		
							4,452		
							3,676		
							5,143		
							2,274		
							6,744		
							<b>73,164</b>		
							33,372		
		140,923			87,540		1,380		
								355	
								340	
								100	
								64,693	
								5,676	
								0	
		<b>140,923</b>	<b>0</b>	<b>0</b>	<b>87,540</b>		<b>34,752</b>	<b>71,164</b>	
		<b>273,309</b>	<b>32,694</b>	<b>33,475</b>	<b>90,430</b>		<b>519,259</b>	<b>2,146,458</b>	<b>75,329</b>
							<b>65,992</b>		
	22,730	133,842		71,468	39,363		187,354		97,309
							37,650		
	<b>22,730</b>	<b>133,842</b>	<b>0</b>	<b>71,468</b>	<b>39,363</b>		<b>225,004</b>		<b>97,309</b>
417,414	67,539						193,287		34,938
									144,663
<b>417,414</b>	<b>67,539</b>						<b>193,287</b>		<b>179,601</b>
		47,021	10,861	28,818	16,635	20,795	174,759		34,333
									41,698
		<b>47,021</b>	<b>10,861</b>	<b>28,818</b>	<b>16,635</b>	<b>20,795</b>	<b>174,759</b>		<b>76,031</b>
							7,920		
<b>417,414</b>	<b>90,268</b>	<b>454,172</b>	<b>43,555</b>	<b>133,761</b>	<b>146,428</b>	<b>20,795</b>	<b>1,186,221</b>	<b>2,146,458</b>	<b>428,270</b>

# NIH Management Fund, Service & Supply Fund, and GSA Rent Fiscal Year 2012

(Dollars in Thousands)



<b>DISTRIBUTION OF NCI PAYMENT</b>	<b>Amount</b>	<b>Share of NCI</b>
Clinical Center	\$113,577	61.0%
Center for Scientific Review	12,209	6.6%
Center for Information Technology	6,645	3.6%
Service and Supply Fund Assessment	18,738	10.1%
Other Research Services	14,532	7.8%
Other OD	20,658	11.1%
*Total Management Fund and SSF	186,359	100.0%
Other NIH Institutes Management Fund and SSF	1,447,716	
Total NIH Management Fund and SSF	\$1,634,075	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

*Clinical Center:* Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, and social work.

*Center for Scientific Review:* Initial scientific review of applications and assignment of research grant applications to institutes.

*Center for Information Technology:* Research and development program in which concepts and methods of computer science are applied to biomedical problems.

*GSA Rental Payments for Space:* All building rental costs, including utilities and guard services.

*Other Research Services:* Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

*Service & Supply Fund:* Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, and biomedical engineering.

## Special Sources of Funds

### CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

NCI CRADA Receipts Deposited to the U.S. Treasury  
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2002	8,864	5,048	2,380
2003	11,533	5,221	5,361
2004	11,351	5,080	5,469
2005	10,962	6,858	4,253
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668

### Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange, and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH.

NCI Royalty Income Funding History  
(Dollars in Thousands)

Years	Collections*	Inventor	
		Payments	Other
2002/2004	42,565	3,961	38,604
2003/2005	27,271	5,262	22,009
2004/2006	26,923	4,950	21,973
2005/2007	34,086	5,745	28,341
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
**2011/2013	69,155	16,392	52,763
**2012/2014	73,060	21,640	51,420

\*Does not include assessments by NIH.

\*\*2011/2013 and 2012/2014 collections and payments are estimates.

### Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997, extended in July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), and again in December 2011 (PL 112-80). This act allows postal customers to contribute funding to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2012, NCI has received \$52,512,541. NCI has used these funds for research projects directed towards breast cancer research. Thus far, four major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer," the "Breast Cancer Research Stamp Exception Program," the "Breast Cancer Premalignancy Program" and a clinical trial to determine the risk of breast cancer recurrence. In FY 2012, \$1.655 million was obligated on Breast Cancer Stamp Fund programs.

## Funding for Various Research Areas

(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.


Disease Area	2008	2009	2010	2011	2012
	Actual	Actual	Actual	Actual	Actual
Total NCI Budget	\$4,827.6	\$4,966.9	\$5,098.1	\$5,058.1	\$5,067.3
AIDS	258.5	265.9	272.1	270.0	271.7
Brain & CNS	153.7	151.5	156.8	172.6	177.5
Breast Cancer	572.6	599.5	631.2	625.1	602.7
Cervical Cancer	76.8	77.8	77.0	81.4	72.6
Clinical Trials	853.2	846.6	852.3	877.8	753.7
Colorectal Cancer	273.7	264.2	270.4	265.1	256.3
Head and Neck Cancers	76.1	77.1	62.7	61.8	65.0
Hodgkins Disease	17.5	18.2	14.6	13.4	15.6
Leukemia	216.4	220.6	239.7	227.0	234.7
Liver Cancer	74.2	70.3	72.6	66.2	64.6
Lung Cancer	247.6	246.9	281.9	296.8	315.1
Melanoma	110.8	103.7	102.3	115.6	121.2
Multiple Myeloma	41.5	45.2	48.5	54.9	61.3
Non Hodgkin's Lymphoma	122.6	130.9	122.4	126.4	119.5
Ovarian Cancer	100.0	110.1	112.3	110.8	111.7
Pancreatic Cancer	87.3	89.7	97.1	99.5	105.4
Prostate Cancer	285.4	293.9	300.5	288.3	265.1
Stomach Cancer	12.4	15.4	14.5	13.4	12.1
Uterine Cancer	17.1	18.0	14.2	15.9	19.1

Note: These figures were created using NCI's coding methodology. More information about this methodology, as well as project listings for these categories and others, are available online through NCI's Funded Research Portfolio

<http://fundedresearch.cancer.gov/>

## Research Project Grants Number of Awards Fiscal Years 2003-2012

*Includes Small Business Innovation Research and Small Business Technology Transfer Awards*



\*EXCLUDES projects awarded with Stamp Out Breast Cancer Funds.

## RPGs Requested and Awarded Fiscal Years 2003-2012

(Dollars in Thousands)

Fiscal Year	Type		Requested		Awarded		Success
2003	Competing	New	5323	\$1,675,039	1222	\$347,446	26.5%
		Renewal	955	447,122	441	194,084	
		Supplement	20	4,671	5	1,338	
		Subtotal	6298	2,126,832	1668	542,868	
	Non-Competing				3467	1,457,144	
	<b>Total</b>				<b>5135</b>	<b>2,000,012</b>	
2004	Competing	New	6,558	\$2,045,451	1,333	\$339,925	23.6%
		Renewal	988	518,201	445	210,790	
		Supplement	24	8,337	7	2,196	
		Subtotal	7,570	2,571,989	1,785	552,911	
	Non-Competing				3,682	1,549,727	
	<b>Total</b>				<b>5,467</b>	<b>2,102,638</b>	
2005	Competing	New	6,357	\$2,239,503	1,086	\$309,507	19.2%
		Renewal	1,050	473,898	335	162,857	
		Supplement	22	6,147	7	1,185	
		Subtotal	7,429	2,719,548	1,428	473,549	
	Non-Competing				3,984	1,656,614	
	<b>Total</b>				<b>5,412</b>	<b>2,130,164</b>	
2006	Competing	New	6,585	\$2,215,548	1,105	\$293,912	19.2%
		Renewal	984	542,799	348	170,110	
		Supplement	13	4,098	2	681	
		Subtotal	7,582	2,762,445	1,455	464,703	
	Non-Competing				3,980	1,633,442	
	<b>Total</b>				<b>5,435</b>	<b>2,098,145</b>	
2007	Competing	New	6,428	\$2,116,286	1,178	\$306,431	20.2%
		Renewal	864	482,655	295	163,225	
		Supplement	12	3,513	2	609	
		Subtotal	7,304	2,602,454	1,475	470,265	
	Non-Competing				3,997	1,582,828	
	<b>Total</b>				<b>5,472</b>	<b>2,053,093</b>	
2008	Competing	New	5,944	\$1,991,089	1,150	\$324,070	21.7%
		Renewal	966	515,784	352	187,458	
		Supplement	1	408	1	338	
		Subtotal	6,911	2,507,281	1,503	511,866	
	Non-Competing				3,877	1,509,611	
	<b>Total</b>				<b>5,380</b>	<b>2,021,477</b>	
2009	Competing	New	6,167	\$2,069,518	1,029	\$320,980	19.4%
		Renewal	1,000	500,201	358	177,853	
		Supplement	5	1,141	1	67	
		Subtotal	7,172	2,570,860	1,388	498,900	
	Non-Competing				3,791	1,564,139	
	<b>Total</b>				<b>5,179</b>	<b>2,063,039</b>	
2010	Competing	New	7,494	\$2,776,315	1,041	\$375,830	16.3%
		Renewal	1,007	591,060	343	183,675	
		Supplement	18	6,805	3	1,491	
		Subtotal	8,519	3,374,180	1,387	560,996	
	Non-Competing				3,692	1,531,733	
	<b>Total</b>				<b>5,079</b>	<b>2,092,729</b>	
2011	Competing	New	8,445	\$3,183,607	962	\$342,196	12.6%
		Renewal	756	454,907	201	104,002	
		Supplement	29	8,871	3	460	
		Subtotal	9,230	3,647,385	1,166	446,658	
	Non-Competing				3,853	1,641,694	
	<b>Total</b>				<b>5,019</b>	<b>2,088,352</b>	
2012	Competing	New	8,414	\$3,220,278	1,020	\$351,601	13.4%
		Renewal	644	397,473	197	103,990	
		Supplement	25	9,860	3	594	
		Subtotal	9,083	3,627,611	1,220	456,185	
	Non-Competing				3,801	1,619,109	
	<b>Total</b>				<b>5,021</b>	<b>2,075,294</b>	

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.

Success rate is the number of awarded grants divided by the number of awards requested.


Totals exclude Assessments for Program Evaluation and projects awarded with Stamp Out Breast Cancer Funds.

## RPG Awards by Activity Codes

### Fiscal Years 2003-2012

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	DP1	DP2	P01	R00	R37	R29	RFA	U01	U19	UH2	UM1	R03	R21	R33	R15	R55	R56	SBIR/ STTR	TOTAL	
2003	#	3,573			178		70	14	252	27				203	360	81	21			356	5,135	
	\$	1,207,387			336,607		35,360	1,584	173,342	31,126				15,207	67,742	37,714	3,086			90,857	2,000,012	
2004	#	3,780			177		73	0	233	26				240	425	96	20			397	5,467	
	\$	1,277,185			344,489		37,888	53	168,539	31,377				18,067	77,970	42,931	4,560			99,579	2,102,638	
2005	#	3,848			176		74		254	30	1			223	430	88	20	2	1	265	5,412	
	\$	1,312,762			338,660		40,007		171,403	34,100	1,049			16,894	76,566	36,250	4,091	200	407	97,775	2,130,164	
2006	#	3,909			173		76		273	26	3			218	405	73	14			2	5,435	
	\$	1,293,880			339,616		40,067		173,304	31,292	4,365			16,558	70,650	28,726	2,983			649	96,055	2,098,145
2007	#	3,849			172		73		285	22	3			284	437	48	19			2	278	5,472
	\$	1,266,622			326,968		38,232		177,423	24,295	4,212			21,640	78,748	16,739	4,042			495	93,677	2,053,093
2008	#	3,732	2		158	2	70		294	25	3			256	466	36	22			2	312	5,380
	\$	1,250,346	1,651		305,250	497	36,287		174,254	20,872	4,366			19,597	92,120	13,770	4,725			302	97,439	2,021,476
2009	#	3,573	3		151	29	63		326	32	2			239	447	25	27	1		261	5,179	
	\$	1,248,939	3,313		302,270	7,186	32,640		218,798	31,320	1,584			18,401	91,537	9,094	5,823	100	79	91,954	2,063,038	
2010	#	3,655	5	1	140	55	61		275	43	1			181	415	16	24				207	5,079
	\$	1,323,673	6,021	2,512	280,531	13,665	31,498		200,424	36,209	1,252			14,195	83,950	5,583	7,539			8	85,669	2,092,729
2011	#	3,648	8		129	71	59		290	65	2	1		127	442	9	23				144	5,019
	\$	1,331,635	7,639		259,230	17,239	30,327		194,142	47,100	5,874	255		9,646	88,481	3,166	9,183				84,054	2,088,352
2012	#	3,526	7	2	122	76	48		326	84	1	1	5	172	439	3	19				190	5,021
	\$	1,318,483	7,289	4,584	243,599	18,531	23,972		204,957	53,457	1,031	100	13,467	13,132	86,384	1,182	7,772				77,355	2,075,295



EXCLUDES projects awarded with the Stamp Out Breast Cancer Funds and Program Evaluation.

\* In 2011, NCI awarded 1 UA5, it is not displayed but is included in the 2011 totals.

## Activity Code Descriptions

R01	<b>Research Project (Traditional)</b> - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
DP1	<b>NIH Director's Pioneer Award (NDPA)</b> - Support for individuals who have the potential to make extraordinary contributions to medical research. Not renewable
DP2	<b>NIH Director's New Innovator Awards</b> support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact. This award complements ongoing efforts by NIH and its institutes and centers to fund new investigators through R01 grants and other mechanisms.
P01	<b>Research Program Projects</b> - broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R00	<b>Research Transition Award</b> - To support the second phase of a Career/Research Transit award program that provides 1-3 years of independent research support (R00) contingent on securing an independent research position. Award recipients will be expected to contract successfully for independent R01 support from the NIH during the R00 research transition award period.
R35	<b>Outstanding Investigator Grants</b> - long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	<b>Methods to Extend Research in Time (MERIT) Award</b> - long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	<b>First Independent Research Support and Transition (FIRST) Award</b> - sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	<b>Request for Applications</b> - A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	<b>Research Project Cooperative Agreement</b> - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
U19	<b>Research Program Cooperative Agreements</b> - support research programs that have multiple projects directed towards specific major objective, basic theme, or program goal, requiring a broad-based, multidisciplinary, and often long-term, approach.
UH2	<b>Exploratory/Developmental Cooperative Agreement Phase I</b> - To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)
UA5	<b>Academic Research Enhancement Award (AREA) Cooperative Agreements</b> - support cooperative agreements for the Academic Research Enhancement Award (AREA) program. AREA supports small scale research projects conducted by faculty in primarily baccalaureate degree-granting domestic institutions.
UM1	<b>Multi-Component Research Project Cooperative Agreements</b> - support large-scale cooperative agreements involving complex clinical trials with multiple components.
R03	<b>Small Grants</b> - research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R15	<b>Academic Research Enhancement Award (AREA)</b> - to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R21	<b>Exploratory/Developmental Grants</b> - Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	<b>Exploratory/Developmental Grants</b> - Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R55	<b>Shannon Awards</b> - limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R56	<b>High-Priority, Short-Term Project Award</b> - provide limited, non-renewable interim support to enable an applicant to gather additional data for revision of a new or competing renewal application.
R41	<b>Small Business Technology Transfer (STTR) Grants - Phase I</b> - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R42	<b>Small Business Technology Transfer (STTR) Grants - Phase II</b> - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R43	<b>Small Business Innovation Research (SBIR) Grants - Phase I</b> - projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to commercial products or services.
R44	<b>Small Business Innovation Research (SBIR) Grants - Phase II</b> - in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

### Cancer Centers by State (P30 Core Grants), Fiscal Year 2012

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$5,726
Arizona	University of Arizona	Comprehensive Core	1	3,954
California	Burnham Institute for Medical Research	Basic Core	1	3,887
	City of Hope/Beckman Research Institute	Comprehensive Core	1	2,225
	Salk Institute for Biological Studies	Basic Core	1	2,936
	Stanford University	Clinical Core	1	3,092
	University of California Davis	Comprehensive Core	1	3,139
	University of California Irvine	Comprehensive Core	1	1,249
	University of California Los Angeles	Comprehensive Core	1	4,576
	University of California San Diego	Comprehensive Core	1	4,282
	University of California San Francisco	Comprehensive Core	1	7,707
University of Southern California	Comprehensive Core	1	6,532	
Colorado	University of Colorado Denver	Comprehensive Core	1	3,596
Connecticut	Yale University	Comprehensive Core	1	600
Dist of Col	Georgetown University	Comprehensive Core	1	1,550
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	2,787
Georgia	Emory University	Clinical Core	1	1,493
Hawaii	University of Hawaii at Manoa	Clinical Core	1	1,150
Illinois	Northwestern University	Comprehensive Core	1	4,830
	University of Chicago	Comprehensive Core	1	4,139
Indiana	Indiana Univ-Purdue Univ at Indianapolis	Clinical Core	1	1,237
	Purdue University West Lafayette	Basic Core	1	1,195
Iowa	University of Iowa	Comprehensive Core	1	2,364
Kansas	University of Kansas Medical Center	Clinical Core	1	1,397
Maine	Jackson Laboratory	Basic Core	1	2,156
Maryland	Johns Hopkins University	Comprehensive Core	1	6,995
	University of Maryland Baltimore	Clinical Core	1	1,565
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	11,165
	Massachusetts Institute of Technology	Basic Core	1	3,854
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	5,695
	Wayne State University	Comprehensive Core	1	2,548
Minnesota	Mayo Clinic Rochester	Comprehensive Core	1	5,471
	University of Minnesota Twin Cities	Comprehensive Core	1	3,430
Missouri	Washington University	Comprehensive Core	1	4,381
Nebraska	University of Nebraska Medical Center	Clinical Core	1	1,428
New Hampshire	Dartmouth College	Comprehensive Core	1	3,126
New Jersey	Robert Wood Johnson Medical School	Comprehensive Core	1	3,002
New Mexico	University of New Mexico	Clinical Core	1	1,934
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	4,257
	Cold Spring Harbor Laboratory	Basic Core	1	4,347
	Columbia University Health Sciences	Comprehensive Core	1	3,816
	New York University School of Medicine	Clinical Core	1	2,512
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	3,960
	Sloan-Kettering Institute for Cancer Res	Comprehensive Core	1	13,436
North Carolina	Duke University	Comprehensive Core	1	5,724
	University of North Carolina Chapel Hill	Comprehensive Core	1	7,072
	Wake Forest University Health Sciences	Comprehensive Core	1	1,393
Ohio	Case Western Reserve University	Comprehensive Core	1	4,849
	Ohio State University	Comprehensive Core	1	4,582
Oregon	Oregon Health and Science University	Clinical Core	1	1,135
Pennsylvania	Fox Chase Cancer Center	Comprehensive Core	1	4,062
	Thomas Jefferson University	Clinical Core	1	2,947
	University of Pennsylvania	Comprehensive Core	1	7,725
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	5,340
	Wistar Institute	Basic Core	1	2,517
South Carolina	Medical University of South Carolina	Clinical Core	1	1,401
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	5,675
	Vanderbilt University	Comprehensive Core	1	5,899
Texas	Baylor College of Medicine	Clinical Core	1	2,935
	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	9,988
	University of Texas San Antonio Health Science Center	Clinical Core	1	1,300
	University of Texas Southwestern Medical Center	Clinical Core	1	1,425
Utah	University of Utah	Clinical Core	1	1,455
Virginia	University of Virginia Charlottesville	Clinical Core	1	2,383
	Virginia Commonwealth University	Clinical Core	1	1,423
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	11,585
Wisconsin	University of Wisconsin Madison	Comprehensive Core	1	4,556
	<b>Total P30s</b>		<b>67</b>	<b>262,089</b>
	Planning Grants (P20s)		16	2,992
	Other P20, P30 & U41		0	9,826
	<b>Total Cancer Centers</b>		<b>67</b>	<b>274,908</b>

## Specialized Programs of Research Excellence, Fiscal Year 2012

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers.


Each SPORE is focused on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. For more information, see <http://trp.cancer.gov>.

Mechanism	Site	No.	Amount
P50 SPOREs	Brain	3	\$4,761
	Breast	6	13,495
	Cervical	1	2,390
	Genitourinary	2	4,332
	Gastrointestinal	5	9,790
	Head and Neck	3	5,944
	Leukemia	2	4,594
	Lung	6	13,586
	Lymphoma	4	9,300
	Myeloma	2	4,600
	Ovarian	4	9,123
	Pancreatic	3	5,667
	Prostate	6	11,397
	Skin	5	11,473
	Uterine	1	2,300
		<b>Subtotal</b>	<b>53</b>
P20	Brain	1	700
	<b>Total P20</b>	<b>1</b>	<b>700</b>
Co-funded	Head & Neck with NIDCR		1
	<b>Total Co-funded</b>		<b>1</b>
<b>Total NCI SPOREs and NCI SPORE Funding</b>		<b>54</b>	<b>\$113,454</b>

# NRSA Predoctoral and Postdoctoral Trainees

## Fiscal Years 2000-2012


(Full Time Trainee Positions)



# Construction/Renovation Funding and Building & Facilities Funding Fiscal Years 2001 - 2012

*(Dollars in Thousands)*

Construction/Renovation grants and contracts were used by grantees to build infrastructure. The grants (C06s) provide matching Federal funds for up to 50% of allowable costs for construction or major remodeling to create new facilities for cancer research. Although the NCI has the authority to fund Construction grants, Congress has not appropriated funds to this program for NCI since FY 2003. In FY 2005, NCI began to receive Building & Facilities funding to use specifically for repairs and improvements at the NCI - Frederick facility.



## Grant and Contract Awards by State Fiscal Year 2012

(Dollars in Thousands)

State	Grants		Contracts		Total	
	No	Amount	No	Amount	No	Amount
Alabama	59	\$31,164	5	\$2,709	64	\$33,873
Arizona	59	31,816	1	187	60	32,003
Arkansas	18	8,466	2	2,200	20	10,666
California	835	418,849	41	31,475	876	450,324
Colorado	87	30,476			87	30,476
Connecticut	94	34,190	1	2,137	95	36,327
Delaware	3	1,966	1	200	4	2,166
District of Columbia	62	25,322	10	3,068	72	28,390
Florida	180	71,100	7	2,575	187	73,675
Georgia	98	31,939	10	5,789	108	37,728
Hawaii	24	19,638	2	1,364	26	21,002
Idaho					0	0
Illinois	242	106,315	15	4,505	257	110,820
Indiana	69	22,604			69	22,604
Iowa	39	16,021	1	4,818	40	20,839
Kansas	31	12,047			31	12,047
Kentucky	51	13,346	1	1,361	52	14,707
Louisiana	41	10,639	1	1,705	42	12,345
Maine	7	4,977			7	4,977
Maryland	237	124,846	59	430,590	296	555,436
Massachusetts	615	352,524	14	7,811	629	360,335
Michigan	223	110,636	2	7,223	225	117,859
Minnesota	187	103,156	6	2,575	193	105,731
Mississippi	5	1,414			5	1,414
Missouri	98	55,772	7	5,323	105	61,095
Montana	1	413	1	1,500	2	1,912
Nebraska	45	21,411			45	21,411
Nevada	3	1,189			3	1,189
New Hampshire	37	19,702	2	275	39	19,977
New Jersey	88	29,446	6	6,116	94	35,562
New Mexico	24	12,419	1	2,319	25	14,738
New York	587	287,390	10	5,517	597	292,907
North Carolina	286	126,184	11	3,046	297	129,230
North Dakota	2	564			2	564
Ohio	214	96,970	7	5,216	221	102,186
Oklahoma	9	2,970	2	3,302	11	6,272
Oregon	48	20,934			48	20,934
Pennsylvania	467	242,116	4	2,016	471	244,133
Rhode Island	30	8,278	2	230	32	8,508
South Carolina	50	18,012			50	18,012
South Dakota	8	3,158			8	3,158
Tennessee	191	98,735	2	1,695	193	100,430
Texas	489	239,155	8	4,631	497	243,786
Utah	56	24,691	2	2,013	58	26,704
Vermont	6	4,904			6	4,904
Virginia	96	54,633	9	4,141	105	58,774
Washington	206	134,766	10	15,759	216	150,525
West Virginia	9	2,352			9	2,352
Wisconsin	99	45,513	1	303	100	45,816
Wyoming	1	182			1	182
<b>Subtotal</b>	<b>6,416</b>	<b>3,135,310</b>	<b>264</b>	<b>575,692</b>	<b>6,680</b>	<b>3,711,003</b>
Guam	1	1,320			1	1,320
Puerto Rico	8	4,702			8	4,702
<b>Total</b>	<b>6,425</b>	<b>3,141,333</b>	<b>264</b>	<b>575,692</b>	<b>6,689</b>	<b>3,717,025</b>

Excludes STAMP, NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

## Grant and Contract Awards by Country Fiscal Year 2012

*(Dollars in Thousands)*

<u>Country</u>	<u>Grant</u>		<u>Contract</u>		<u>Total</u>	
	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>	<u>No</u>	<u>Amount</u>
Argentina	0	\$75			0	\$75
Australia	4	904			4	904
Belgium	1	235			1	235
Canada	19	9,037	2	\$1,543	21	10,580
Costa Rica			2	2,866	2	2,866
France	6	4,125			6	4,125
India	1	196			1	196
Ireland	1	184			1	184
Israel	5	1,200			5	1,200
Korea	1	171			1	171
Malawi	0	150			0	150
Netherlands	1	217	1	90	2	307
Spain	1	224			1	224
Switzerland	1	624			1	624
United Kingdom	6	1,208	2	43	8	1,251
<b>Total Foreign</b>	<b>47</b>	<b>18,552</b>	<b>7</b>	<b>4,542</b>	<b>54</b>	<b>23,019</b>

Excludes STAMP, NRSA TAP, Loan Repayment Program, Program Evaluation, and other assessments and miscellaneous expenses.

## Institutions Receiving More than \$15 Million in NCI Support, FY 2012

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	\$25,402	\$2,225	\$27,627
Arizona	University of Arizona	20,590	187	20,777
California	Burnham Institute for Medical Research	20,030		20,030
	City of Hope's Beckman Research Institute	25,524		25,524
	Stanford University	44,303		44,303
	University of California System	158,382	2,479	160,861
	University of Southern California	38,968	2,486	41,454
Colorado	University of Colorado Health Sciences Center	22,114		22,114
Connecticut	Yale University	28,235		28,235
District of Columbia	Georgetown University	19,221	1,504	20,725
Florida	H. Lee Moffitt Cancer Center & Research Institute	35,013	735	35,748
Georgia	Emory University	20,223	2,437	22,660
Hawaii	University of Hawaii at Manoa	17,898	1,364	19,262
Illinois	Northwestern University	30,179	382	30,561
	University of Chicago	29,183	1,433	30,616
	University of Illinois at Chicago	19,706	247	19,953
Iowa	University of Iowa	13,973	4,818	18,791
Maryland	The Johns Hopkins University	79,738	4,857	84,595
	SAIC-Frederick, Inc.		238,204	238,204
	Westat, Inc.		23,697	23,697
	Gynecologic Oncology Group	18,470		18,470
Massachusetts	Beth Israel Deaconess Medical Center	19,784		19,784
	Brigham and Women's Hospital	52,563	25	52,588
	Broad Institute, Inc.	24,233		24,233
	Dana-Farber Cancer Institute	74,463		74,463
	Harvard University	21,122		21,122
	Massachusetts General Hospital	45,618	15	45,633
	Massachusetts Institute of Technology	23,314		23,314
University of Massachusetts Medical School Worcester	13,351		13,351	
Michigan	University of Michigan at Ann Arbor	73,576		73,576
	Wayne State University	17,438	4,784	22,222
Minnesota	Mayo Clinic in Rochester	64,128	1,015	65,143
	University of Minnesota	33,956	171	34,127
Missouri	Washington University	50,552	268	50,820
Nebraska	University of Nebraska Medical Center	18,024		18,024
New Hampshire	Dartmouth College	19,211	25	19,236
New York	Columbia University Health Sciences	34,228		34,228
	Mount Sinai School of Medicine	24,137		24,137
	New York University	18,742		18,742
	Roswell Park Cancer Institute Corporation	29,312		29,312
	Sloan-Kettering Institute for Cancer Research	69,849	1,670	71,519
	University of Rochester	15,878		15,878
	Yeshiva University	24,997		24,997
North Carolina	Duke University	39,015	25	39,040
	University of North Carolina at Chapel Hill	59,385		59,385
Ohio	Case Western Reserve University	21,486		21,486
	Ohio State University	45,474	1,121	46,595
Pennsylvania	University of Pennsylvania	60,712		60,712
	University of Pittsburgh	51,958	449	52,407
	Wistar Institute	15,005		15,005
Tennessee	St. Jude Children's Research Hospital	24,170		24,170
	Vanderbilt University	65,841		65,841
Texas	Baylor College of Medicine	41,624		41,624
	University of Texas, MD Anderson Cancer Center	117,206	1,739	118,945
	University of Texas, SW Medical Center at Dallas	18,166		18,166
Utah	University of Utah	22,002	1,813	23,815
Virginia	American College of Radiology	21,949		21,949
	University of Virginia at Charlottesville	16,096		16,096
Washington	Fred Hutchinson Cancer Research Center	82,478	3,653	86,131
	University of Washington	34,269		34,269
Wisconsin	University of Wisconsin	30,281	303	30,584
	<b>Total</b>	<b>\$2,202,742</b>	<b>\$304,131</b>	<b>\$2,506,873</b>

Includes Manpower Development Grants

## Appropriations of the NCI 1938-2012

(In Whole Dollars)

Year	Amount	Description
<b>1938 - 2001</b>	<b>\$48,750,577,220</b>	
2002.....	4,190,405,000	prior to reductions in PL 107-116(-\$4,524,000 via the Secretary's 1% transfer authority, -\$2,054,000 for the enacted rescission, -\$7,118,000 administrative reduction and -\$8,000 lapse). Includes \$254,396,000 of AIDS funding.
2003.....	4,622,394,000	prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and -\$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004.....	4,770,519,000	prior to reductions in PL 108-199(-\$3,136,000 for Labor/HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
2005.....	4,865,525,000	prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.
2006.....	4,841,774,000	prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,866,000 of AIDS funding.
2007.....	4,797,639,000	prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,866,000 of AIDS funding.
2008.....	4,827,556,000	Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009.....	4,968,973,000	prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4000 lapse). Includes \$265,882,000 of AIDS funding.
2010.....	5,103,388,000	prior to -\$760,000 HHS Secretary's transfer ,-\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
2011.....	5,058,577,000	prior to \$472,000 lapse. Includes \$269,953,000 of AIDS funding.
2012.....	5,072,183,000	prior to -\$1,445,000 HHS Secretary's transfer ,-\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse.Includes \$271,692,000 of AIDS funding.
<b>1938-2011</b>	<b>101,869,510,220</b>	

## Bypass Budget Requests Fiscal Years 1974-2012

(in Whole Dollars)


Fiscal Year	Request	Fiscal Year	Request
1974.....	640,031,000	2000.....	3,873,000,000
1975.....	750,000,000	2001.....	4,135,000,000
1976.....	898,500,000	2002.....	5,030,000,000
1977.....	948,000,000	2003.....	5,690,000,000
1978.....	955,000,000	2004.....	5,986,000,000
1979.....	1,036,000,000	2005.....	6,211,000,000
1980.....	1,055,000,000	2006.....	6,170,000,000
1981.....	1,170,000,000	2007.....	5,949,714,000
1982.....	1,192,000,000	2008.....	5,865,788,000
1983.....	1,197,000,000	2009.....	6,028,386,000
1984.....	1,074,000,000	2010.....	7,193,393,000
1985.....	1,189,000,000	2011.....	6,199,666,000
1986.....	1,460,000,000	2012.....	5,869,857,000
1987.....	1,570,000,000	2013.....	5,833,010,000
1988.....	1,700,000,000	2014.....	To be determined*
1989.....	2,080,000,000		
1990.....	2,195,000,000		
1991.....	2,410,000,000		
1992.....	2,612,000,000		
1993.....	2,775,000,000		
1994.....	3,200,000,000		
1995.....	3,600,000,000		
1996.....	3,640,000,000		
1997.....	2,977,000,000		
1998.....	2,702,500,000		
1999.....	3,191,000,000		

The National Cancer Act in December 1971 included a provision for the Director, NCI, to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

\*As of publication, the FY 2014 figures were still under development. When figures are finalized they will be available online at <http://www.cancer.gov>.

## Bypass Requests and Appropriations of the NCI Fiscal Years 1974-2013

---





\*As of publication, the FY 2014 figures were still under development. When figures are finalized they will be available online at <http://www.cancer.gov>.

# Comparison of Dollars, Positions, and Space Fiscal Years 2003-2012

Funds are obligations against the annual appropriation in millions of dollars.

FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.

Space is in thousands of square feet, excluding NCI-Frederick.



## Personnel Resources

### Fiscal Years 2002-2012

---


Fiscal Year	Full Time Permanent Appointment	Other than Full Time Permanent	Training Fellows	Total Personnel Resources
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305
2005	1,959	882	1,077	3,918
2006	2,579	289	1,113	3,981
2007	2,421	498	1,111	4,030
2008	2,075	920	1,016	4,011
2009	2,118	959	1,058	4,135
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042

# AIDS Funding History

## Fiscal Years 1996 - 2012

---

Fiscal Year	NCI	NIH	% NCI of NIH
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%
2005	265,907	2,909,381	9%
2006	253,666	2,902,183	9%
2007	253,666	2,904,536	9%
2008	258,499	2,928,300	9%
2009	265,882	3,019,279	9%
2010	272,130	3,085,597	9%
2011	269,953	3,059,243	9%
2012	271,692	3,076,056	9%





**NIH Publication No. 13-7874**  
**Printed July 2013**

